



Carbone Cancer Center

UNIVERSITY OF WISCONSIN
SCHOOL OF MEDICINE AND PUBLIC HEALTH

December 31, 2022

Cancer Research Tax Check-off Program

Reporting Period: January 1, 2005 – December 31, 2022

BACKGROUND

In April 2004, Assembly Bill 351, establishing a breast cancer research program tax check-off, was signed into law as 2003 Wisconsin Act 176. Under its provisions, every individual filing a Wisconsin income tax return may provide any amount of additional payment or refund to support the breast cancer research program. Senate Bill 321, which revises the administration of the individual tax check-offs available under Wisconsin law, became law under 2011 Wisconsin Act 222 in April 2012. This law consolidates the breast and prostate cancer options into a single cancer research check-off option.

Under Act 222, the amount received, after administrative expenses are deducted, is divided evenly between the Medical College of Wisconsin (MCW) and the University of Wisconsin Carbone Cancer Center (UWCCC). The money must be used for cancer research and may not be used to supplant other funds available.

This funding comes at a time when opportunities abound to leverage the research capabilities at both institutions to make a significant difference for the citizens of Wisconsin in the outcomes attributed to this disease. Research conducted in Wisconsin in collaboration with colleagues around the country is directly responsible for advances in breast cancer prevention, detection and treatment that are reflected in encouraging cancer statistics. Breast cancer death rates in Wisconsin declined 41 percent since the mid-1990s, from 29.57 deaths per 100,000 in 1995 to 17.28 per 100,000 in 2017 (the most recent year for which data are available). The state also saw a rapid drop in the rate of new breast cancer diagnoses between 2000 and 2004 (from 141.6 per 100,000 to 119.9 per 100,000). However, since then the incidence of the disease has not changed. In 2005, the incidence rate was 152.47 per 100,000 and in 2016 the rate was 161.00 per 100,000.

Continued commitment in our state to innovate approaches to cancer prevention, outreach, screening and treatment is essential to continue to reduce the rate of new cancer diagnoses and deaths. Over time these resources have been used to support programs that increase access to treatment facilities in rural areas and increase outreach efforts that promote screening. This investment has had a positive impact, with 78% of Wisconsin women over 40 having had a mammogram within the past two years in 2016. While there is still room for improvement to reach the Wisconsin Comprehensive Cancer Control Plan's goal of 90% screened by 2020, the state has observed an increase in breast cancer that is diagnosed in the earlier stages (in situ), from 13 to 18.7 percent over 1996 to 2016. Among invasive breast cancers, there was also an increase in the percent diagnosed at the localized (non-metastatic) stage from 58 percent to 66 percent between 1995 and 2016. Despite this progress, breast cancer remains the leading cause of cancer in women in Wisconsin and cancer as a whole now exceeds heart disease as a major cause of mortality. For these reasons, continued research is needed to identify ways to prevent breast cancer, to increase the proportion of women who are getting mammograms and to develop more effective treatments for both early- and late-stage disease.

The UWCCC remains committed to its goals: 1) to conduct the highest quality research into the origins and control of cancer; 2) to translate these research findings to evaluation in the clinic through well-designed clinical trials with corresponding biologic endpoints whenever possible; and 3) to provide the best care possible to all cancer patients by carefully integrating high quality, cutting-edge care with clinical research in a compassionate and individualized manner.

The UWCCC primary catchment area consists of 36 counties in southern Wisconsin, with a population of 3,481,168 in 2015, or about 58% of the state's population. Of this catchment area population, 70% live in urban areas, 22% live in rural areas, and 8% live in frontier areas. In total, 91% of the catchment area population is white and 9% is non-white (3% black, 1% American Indian, 3% Asian, and 2% multi-racial). In terms of ethnicity, 6.0% of the catchment area is Hispanic. Overall, the catchment area is representative of the demographic and racial/ethnic diversity of the state.

RESEARCH PROJECT SELECTION

For many years, the UWCCC has used the same well-tested process for identifying innovative early pilot projects for funding. We use our typical pilot project procedure for soliciting, reviewing and awarding pilot projects in cancer research that will be funded by the tax check-off. A solicitation of proposals is sent to all cancer center members defining the subject matter and criteria for selection. Proposals are reviewed and ranked by the UWCCC Scientific Review Committee. This Committee, appointed by the Director, is comprised of established Cancer Center scientists with broad representation across the many disciplines that makeup the UWCCC membership. The Committee assesses the scientific merit of the proposal as well as the likelihood that the funding will produce important results, in a method similar to that used by an NIH study section. The committee evaluates, scores, and ranks the proposals in order to provide the Director recommendations for funding. All studies have Human Subjects, Animal Safety and Biological Safety approvals before commencing (if applicable).

PROGRESS REPORT ON FUNDED CANCER RESEARCH PROJECTS

This progress report covers the funding received from the cancer research tax check-off program from FY05 thru current year, totaling \$1,506,933

Development of High Throughput Cell Culture System for Breast Cancer Research

PI: David Beebe, PhD

The project supports the development of micro scale tools to enable novel biological insights into cancer biology. A focus has been the development of improved methods to capture and analyze circulating tumor cells from prostate and breast cancer patients (in collaboration with Doug McNeel, Josh Lang, Kari Wisinski, Amy Tevaarwerk).

Developing a DNA Sample Collection from DCIS Case Controlled Population

PIs: Michael Gould, PhD & Amy Trentham-Dietz, PhD

Breast cancer risk is a polygenic trait. To identify breast cancer modifier alleles that have a high population frequency and low penetrance we used a comparative genomics approach. Quantitative trait loci (QTL) were initially identified by linkage analysis in a rat mammary carcinogenesis model followed by verification in congenic rats carrying the specific QTL allele under study. The Mcs5a locus was identified by fine-mapping Mcs5 in a congenic model. Here we characterize the Mcs5a locus, which when homozygous for the Wky allele, reduces mammary cancer risk by 50%. The Mcs5a locus is a compound QTL with at least two noncoding interacting elements: Mcs5a1 and Mcs5a2. The resistance phenotype is only observed in rats carrying at least one copy of the Wky allele of each element on the same chromosome. Mcs5a1 is located within the ubiquitin

ligase Fbxo10, whereas Mcs5a2 includes the 5' portion of Frmpd1. Resistant congenic rats show a down-regulation of Fbxo10 in the thymus and an up-regulation of Frmpd1 in the spleen. The association of the Mcs5a1 and Mcs5a2 human orthologs with breast cancer was tested in two population-based breast cancer case-control studies (approximately 12,000 women). The minor alleles of rs6476643 (MCS5A1) and rs2182317 (MCS5A2) were independently associated with breast cancer risk. The minor allele of rs6476643 increases risk, whereas the rs2182317 minor allele decreases risk. Both alleles have a high population frequency and a low penetrance toward breast cancer risk.

Added Value of Advanced Methods for Breast MRI Diagnosis

PI: Frederick Kelcz, MD, PhD

We are testing newer MRI methods, specifically, diffusion weighted imaging (DWI), Blood Oxygen Level Dependent (BOLD) imaging, MR Spectroscopy (MRS) and very high temporal resolution imaging to determine if these methods may add value to our routine breast MRI set of sequences.

A Biologic Study to Evaluate the Feasibility of Detecting a Potential Molecular Marker, CRD-BP, in Metastatic Colon and Breast Cancers

PI: William Schelman, MD, PhD

This project is a pilot study to assess the feasibility of a rapid new cancer detection test for CDP-BP mRNA in blood from patients with previously untreated, metastatic colon and breast cancers. The assay involves performing a reverse transcriptase polymerase chain reaction (RT-PCR) on the RNA from circulating cancer cells obtained from blood samples. Thus, the test is sensitive, noninvasive and relatively inexpensive. The RT-PCR findings will be correlated to protein expression in paraffin embedded tissue from the patients' original biopsies. Findings from this study will provide support for a larger study to assess the specificity and sensitivity of the CRD-BP assay in early colon and breast cancer detection and may also provide a therapeutic target for future drug development.

Developing a Mouse Model to Mechanistically Interrogate the Prostate Cancer Risk Associated 8a24 Genomic Regions

PI: Michael Gould, PhD

Variants in the human 8q24 gene desert have been associated with various types of cancer including prostate, colorectal and breast cancer. A hotspot of cancer-associated variants is located on chr 8, between 128 Mb and 129 Mb, roughly 200 Kb upstream of the transcriptional start site of the proto-oncogene MYC. The non-protein coding nature of the polymorphisms suggests that the causative variants may be implicated in gene expression regulation, with MYC as the obvious strong candidate. Recently, however, a functional prostate cancer susceptibility variant in 8q24 was shown to associate with transcript levels of PVT1, a pre-miRNA transcript located downstream of MYC. It is currently unknown if MYC and/or PVT1 are under control of genetic elements in the 8q24 gene desert region in a tissue-specific manner and if deregulated expression of MYC and/or PVT1 has phenotypic consequences. Using mice clone-assisted genome editing, we genetically engineered a mouse model to address these questions.

The Role of Stroma in Promoting Metastasis in Human Breast Cancer

PI: Mark Burkard, MD, PhD

Metastatic breast cancer is an incurable disease. As such, primary therapy immediately after diagnosis is focused on eradicating early stage disease and preventing metastases. Current predictors of adjuvant therapy benefit are primarily based on anatomic distribution and properties of the primary tumor. An increasing body of evidence has highlighted the additional important roles of non-cancerous portions of tumor, i.e. stroma, in promoting or hindering tumor growth and metastasis. This study seeks to determine whether the breast stromal microenvironment is an important determinant of tumor growth and metastatic potential in early-stage breast cancer. If this is the case, it will lead to further studies to identify chemokines or cellular receptors that mediate stroma-tumor effects. Such factors may serve as biomarkers, allowing improved patient selection for adjuvant therapy. They could also serve as therapeutic targets for new treatments.

Arrayed Microchannels to Improve Circulating Tumor Cell (CTC) Capture and Analysis

PI: David Beebe, PhD

The ability to measure and characterize tumor cells circulating in the blood is evolving as a useful marker of tumor progression and a potential minimally invasive means to guide therapeutic decisions. Current technologies simply count tumor cells but do not allow function assays. If CTCs can be cultured and subjected to functional or molecular characterization, they will provide insight into tumor biology. This ability will facilitate our discovery of target individualized cancer therapies. This project will develop a microfluidic assay that can be easily interfaced with existing capture methods and provide the ability to perform functional and genetic assays of CTCs.

Obesity and the Quality of Breast and Prostate Cancer Care

PI: Amy Trentham-Dietz, PhD

There has been speculation that the quality of care that a patient receives could be related to various physical conditions such as obesity. This project will link data from two studies currently underway to jointly examine the quality of care from the patient perspective in relation to whether the treatment received was consistent with recommended guidelines for breast and prostate cancer or whether obesity played a role in the decision process.

The Role of Fusion Genes in Breast Cancer

PI: Mark Burkard, MD, PhD

Recent studies have shown that fusion genes, long known to be involved in hematologic malignancies, are also important in solid tumors. One study identified over forty candidate fusions in a single breast cancer cell line, but the importance of these fusions is unknown. These fusion genes may be oncogenic (promoting cancer growth), and thus useful for predicting response to therapy. This study will identify the oncogenic potential of known fusion genes. Being able to identify fusion genes with oncogenic potential in a patient's tumor sample could have significant impact on treatment decisions and clinical management. They could be used as therapeutic targets or markers to predict therapeutic effectiveness.

Feasibility Imaging Studies for Triple Negative Breast Cancer (TNBC) Project

PI: Wei Xu, PhD

Triple negative breast cancer is associated with poor clinical outcomes. These patients do not benefit from known hormonal or molecular therapies. Recent studies have shown that Estrogen Receptor (ER)-beta is present in 50-80% of TNBC and that activation of ER-beta inhibits cell growth in cell based assays and animal models, providing the potential for effective treatment for these patients. This small feasibility study will conform that the ER-beta can be identified with PET and optical imaging and provide a method that is superior to immunohistochemical identification that is notoriously poor due to sampling errors that arise from tumor heterogeneity.

Monitoring of Estrogen Receptor-Targeted Cancer Therapy with ¹⁸F-Fluoroestradiol PET

PI: Weibo Cai, PhD

Positron emission tomography (PET) imaging with ¹⁸F-Fluoroestradiol (18F-FES) has been well-established for predicting hormone response in ER α -positive breast cancers. However, whether 18F-FES can be taken up by ER β -positive triple-negative breast cancer (TNBC) remains unknown. Our ultimate goal is to develop/validate

18F-FES PET as a screening tool in TNBC patients to predict their response to ER β -based treatment. To test the proof-of-principle, the proposed research will determine if 18F-FES PET can measure ER β expression and activity in TNBC.

Identify the Key Chemical Groups that Define Selective ERB/AHR Ligands

PI: Yongna Xing, PhD

Estrogen receptor (ER) and aryl hydrocarbon receptor (AHR) responds to broad cellular and environmental chemicals with shared characteristics of ligand promiscuity and ligand-specific physiological consequences. Understanding the structural basis of ligand-specific signaling is crucial for modulating the function of the receptors in cancer and autoimmune disease.

Identification of ER β -specific Effectors in Breast Cancer

PI: Wei Xu, PhD

In order to follow ER β functionality in triple-negative breast tumors, we propose to identify ER β effector proteins from established breast cancer cell lines. These effectors will be used for monitoring clinical response in a Phase II clinical trial operated at UWCCC.

NaF PET/CT Repeatability, Responsiveness, and Response Assessment in Patients with Metastatic Castrate-Resistant Prostate Cancer to Bone Treated with Docetaxel-Based Chemotherapy

PI: Glenn Liu, MD

Metastatic prostate cancer causes significant morbidity as it is commonly associated with the development of bone metastases. Drug development and patient management have been hampered because we do not have a good way to assess treatment response in bone. Imaging is commonly used to assess treatment response in soft tissue metastasis; however, its application in bone metastasis is limited to diagnosis and staging only. Our main goal is to develop innovative quantitative total bone imaging (QTBI) methodology that would lead to selection of candidate imaging biomarkers and enable quick assessment of treatment response in bone. QTBI is based on: (1) extraction of comprehensive functional bone information, and (2) quantitative assessment of all metastatic lesions. We propose using ¹⁸F-Sodium Fluoride (NaF) PET/CT in combination with innovative image analysis methodologies to create a functional profile of the total bone, and extract a complete panel of imaging parameters for use in treatment response assessment. Our hypothesis is that QTBI will more quickly and more accurately identify patient response to therapy.

The Role of TPL2 Kinase in Regulating Macrophage-Myeloma Tumor Cell Interactions

PI: Fotis Asimakopoulos, MBBChir, PhD

Project goals: We hypothesize that monocytes/macrophages play a major, and hitherto poorly appreciated, regulatory role within myeloma niches. Macrophage activation and cytokine secretion is regulated by the serine/threonine kinase TPL2, a MAP3Kinase at the interface of the MAPK and NF κ B pathways. We recently reported constitutive activation of TPL2 kinase-dependent pathways that regulate the magnitude and extent of proinflammatory activity of monocytes/macrophages within myeloma niches. Moreover we uncovered a cell autonomous, growth-promoting role of TPL2 in myeloma tumor cells. To make these discoveries, we used primary CD14+ (monocytic) and CD138+ (tumor) cells from our extensive tissue bank of over 300 myeloma bone marrows. Based on our preliminary data, we hypothesize that TPL2 kinase activity is essential to control macrophage activation and to regulate macrophage-tumor cell interaction in myeloma niches. We propose two

Aims to further investigate the role of TPL2 in regulating macrophage-tumor cell interactions in vivo as well as to harness the effect of TPL2 on macrophage polarization therapeutically.

2016

Translating Novel Breast Cancer Genetic Markers from the Bench to the Clinic to Advance Precision Medicine

- PI: Elizabeth Burnside Professor Radiology
- Co-I: Amy Trentham Dietz Professor Population Health Sciences
- Co-I: David Page Professor Biostatistics and Medical Informatics
- Co-I: James Schull Professor Oncology
- Co-I: Ming Yuan Professor Statistics

Project Goals: Broad studies examining entire genomes of breast cancer patients are identifying a growing list of individual parts of DNA sequences called single nucleotide polymorphisms, or SNPs, that appear to predict the risk of developing breast cancer. But even as more SNPs are found, improvements in risk prediction have been modest.

Dr. Burnside worked to bridge the gap between laboratory discovery and clinical practice in assessing patient risk for breast cancer. Basic research has identified many DNA sequences that correlate with a patient’s breast cancer risk, but updating clinical breast cancer risk assessment tools to include that data is a slow process. Dr. Burnside’s efforts include both (1) Creating updated, more effective models for evaluating a patient’s breast cancer risk and (2) Developing strategies to more rapidly translate and incorporate laboratory discoveries into clinical risk assessments.

UW-Center for Tobacco Research and Intervention (UW-CTRI) Tobacco Cessation Academic Detailing with the Wisconsin Oncology Network (WON) Cancer Clinics/Centers 2016

Project Goals: For CY 2016, UW-CTRI committed to providing onsite, telephone, and electronic academic detailing with the Wisconsin Oncology Network (WON) to implement evidence-based clinical tobacco cessation interventions. The WON activities are in support of the University of Wisconsin Carbone Cancer Center’s (UWCCC) cancer prevention and tobacco cessation efforts.

Activities for CY 2016

- A. The University of Wisconsin Center for Tobacco Research and Intervention (UW-CTRI) Director of Outreach (Robert Adsit) in collaboration with Kari Wisinski, MD and Ryan Mattison, MD, Co-Directors of the WON, **provided tailored training and technical assistance to help the following 16 WON Clinics with integration of evidence-based tobacco cessation treatment interventions:**

WON-Aspirus Regional Cancer Center
WON-Aurora Advanced Health Care-Racine
WON-Aurora Cancer Care-Wauwatosa
WON-Aurora Health Care
WON-Aurora Vince Lombardi Cancer Clinic Sheboygan
WON-Fox Valley Hematology and Oncology
WON-Froedtert Lung Cancer Clinic
WON-Green Bay Oncology
WON-Gundersen Health System
WON-Marshfield Clinic-Marshfield
WON-Marshfield Clinic-Weston Center
WON-Mercy Health Systems Oncology Clinic
WON-University of Wisconsin-Carbone Cancer Center
WON-UW Cancer Center-Johnson Creek

WON-UW Cancer Center-Riverview
WON-UW Health-1 South Park Oncology Clinic

UW-CTRI Outreach staff contacted each of the WON Centers based in Wisconsin with an offer of onsite tobacco cessation technical assistance. This offer included:

1. An assessment of their current practices to identify and treat their patients who use tobacco; and,
2. An invitation to collaboratively develop and implement a tobacco cessation training and technical assistance plan to meet their specific needs and workflow.

During CY 2016, UW-CTRI Outreach staff **completed 71 phone, in-person, and email training and technical assistance contacts with 247 staff at 16 of the WON Clinic sites listed above.**

Sites differed markedly regarding their stage of incorporating evidence-based tobacco dependence treatment. Our work with all of the Clinics/Centers is ongoing.

- B. UW-CTRI wrote in collaboration with UWCCC co-authors an article for publication in the *Wisconsin Medical Journal* describing the baseline tobacco cessation work by the Wisconsin Oncology Network (WON) Cancer Clinics/Centers. Drs. Wisinski and Mattison who co-direct the WON, and Dr. Howard Bailey, UWCCC Director are co-authors along with key UW-CTRI staff. The article was published in the June 2016 edition of the *Wisconsin Medical Journal*.

Other 2016 Outcomes

This fund has also been used for the recruitment of two faculty; Dr. Ruth O'Regan and Dr. Lisa Cadmus-Bertram. Dr. O'Regan serves as Division Head, Hematology/Oncology, and Associate Director of Faculty Development and Education, UW Carbone Cancer Center. She is an internationally recognized breast cancer physician and researcher. Dr. O'Regan was previously a professor of hematology and medical oncology at Emory University, where she held the Louisa and Rand Glenn Family Chair in Breast Cancer Research and was the medical director at Glenn Family Breast Center of Emory University, director of the Breast Cancer Translational Research Program at the Winship Cancer Institute and chief of hematology and medical oncology at the Georgia Cancer Center for Excellence at Grady Memorial Hospital. With a highly active research program focused on identifying mechanisms of resistance to breast-cancer therapies and development of new therapies, Dr. O'Regan has been principal investigator for numerous grants and clinical trials. Her current research is focused on the development of novel therapeutic approaches to treat resistant breast cancers, including triple negative breast cancer. Dr. O'Regan has received multiple awards and is ranked by Newsweek/Castle Connolly Medical as one of the top oncologists in the nation.

Dr. Cadmus-Bertram's research focuses on the role of physical activity and obesity in cancer incidence and survivorship, with a special interest in the use of consumer-based technologies to promote healthy lifestyles. She has been the recipient of several NCI funded projects including a four year NIH Career Development Award entitled "Sedentary Behavior And Breast Cancer: Interventions And Biomarkers."

The fund has also been used to cover salary for the Phase I clinical research group including coordinator time, nurse time in clinic and trial activation specialists. Phase I research is research that tests a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects. Phase I clinical trials are historically underfunded and therefore need supplementation from institutional sources.

2017

Barriers and Opportunities for Breast Cancer Screening and Risk Reduction Among African American Women

PI(s): Dr. Ruth O'Regan and Dr. Kristen Malecki

Dr. O'Regan and Dr. Malecki investigated the factors that contribute to disproportionately worse breast cancer outcomes and survival in African American women. This project involves a multi-pronged approach of (1) Identifying what these risk factors are, (2) Working with community organizations and groups to determine current cancer knowledge and awareness among African American women, including any recurring questions or concerns, and (3) Developing more effective communication tools and support systems to help African American women understand and minimize their cancer risk.

UW-Center for Tobacco Research and Intervention (UW-CTRI) Tobacco Cessation Academic Detailing with the Wisconsin Oncology Network (WON) Cancer Clinics/Centers 2017

PI: Michael Fiore, MD, MPH, MBA, Director, UW-CTRI

Report prepared by: Rob Adsit, MEd, Director of Outreach Programs, UW-CTRI, ra1@ctri.wisc.edu

Goal

For CY 2017, UW-CTRI committed to providing onsite, telephone, and electronic academic detailing with the Wisconsin Oncology Network (WON) to implement evidence-based clinical tobacco cessation interventions. The WON activities are in support of the University of Wisconsin Carbone Cancer Center's (UWCCC) cancer prevention and tobacco cessation efforts.

Activities for CY 2017

A. The University of Wisconsin Center for Tobacco Research and Intervention **provided tailored training and technical assistance to help the following 6 WON Clinics with integration of evidence-based tobacco cessation treatment interventions:**

WON-Hospital Sisters Health System Eastern Division

WON-Green Bay Oncology

WON Fox Valley Hematology and Oncology

WON-Aspirus Regional Cancer Center

WON-Gundersen Health System

WON-Marshfield Clinic-Weston Center

During CY 2017, UW-CTRI Outreach staff **completed 71 phone, in-person, and email training and technical assistance contacts with 138 staff at the 6 WON Clinic sites listed above.**

Sites differed markedly regarding their stage of incorporating evidence-based tobacco dependence treatment. Our work with all of the Clinics/Centers included:

- Determining patient visit flow; helping define and design staff and clinician roles and workflow relative to the identification of, intervention with, and documentation of patients who use tobacco.
- Providing training and technical assistance about brief, practical, evidence-based tobacco cessation interventions, including EHR modifications.
- Identifying and integrating sources of tobacco cessation treatment extenders, including in-clinic and in-community tobacco cessation resources as well as the Wisconsin Tobacco Quit Line.

Overall, the WON Clinics are working to make the delivery of evidence-based tobacco cessation the standard of care for all of their patients.

Support of Breast Cancer Therapies

Research focused on the development of novel therapeutic approaches to treat resistant breast cancers, including triple negative breast cancer.

20/20: Translating Novel Breast Cancer Genetic Markers from the Bench to the Clinic

PI: Dr. Elizabeth Burnside

Dr. Burnside worked to bridge the gap between laboratory discovery and clinical practice in assessing patient risk for breast cancer. Basic research has identified many DNA sequences that correlate with a patient's breast cancer risk, but updating clinical breast cancer risk assessment tools to include that data is a slow process. Dr. Burnside's efforts include both (1) Creating updated, more effective models for evaluating a patient's breast cancer risk and (2) Developing strategies to more rapidly translate and incorporate laboratory discoveries into clinical risk assessments.

2018

Oncology and Primary Care Pilot Study.

For this pilot study, researchers will conduct focus groups with smokers as well as interviews with healthcare staff in oncology settings and primary care settings. The overarching goal of the proposed research is to develop a novel intervention to increase engagement in, and access to, evidence-based smoking-cessation treatment within a clinic setting with minimal staff burden. The research will provide the necessary foundation to develop a novel intervention known as the Learn, Connect and Quit (LCQ) mobile application. Using focus groups, researchers will:

1. Determine the feasibility and acceptability of using mobile technology within the clinic exam room to present treatment-engagement focused content to oncology and primary care patients.
2. Identify key content and design features to maximize utilization of the mobile technology and engagement in evidence-based treatment.
3. Develop pilot content and determine the acceptability and engagement with the content.

\$25,000. *Funded by University of Wisconsin Carbone Cancer Center's (UWCCC), and the National Cancer Institute of NIH. Dr. Megan Piper, PI.*

Support of Breast Cancer Therapies in Dr. Ruth O'Regan's lab

Dr. O'Regan's recent focus is on the development of novel therapeutic strategies for triple negative breast cancer. She demonstrated reciprocal regulation of ZEB1 and androgen receptor in triple negative breast cancer cells, an important finding given the increasing interest in the role of androgen receptor in this subtype of breast cancer. Her work also noted additive effects of lapatinib and rapamycin in triple negative breast cancers, which led to the development of a clinical trial (NCT01272141). They demonstrated that IGF1R knockdown induces mesenchymal to epithelial transition and that IGF1R can be blocked with FAK inhibition in triple negative breast cancer cells, a finding they hope to take to the clinic in the near future.

2019

Breast Cancer Research Study Pilot:

Barriers and Opportunities for Breast Cancer Screening and Risk Reduction among African American Women
PIs: Ruth O'Regan MD, Kristen Malecki PhD MPH

The following are the project Aims:

- Aim 1: To assess African American women's knowledge of, and questions about, personal breast cancer risk including neighborhood (environmental) contexts and life experiences that may increase this risk, and opportunities to mitigate these risks;
- Aim 2: To examine knowledge and beliefs regarding breast cancer screening benefits and recommendations, and how they apply to personalized screening decisions; and
- Aim 3: To determine opportunities to improve knowledge and reduce barriers regarding breast cancer prevention, risk-reduction and effective screening practices among African American women.

To achieve these Aims, we had two objectives to (1) conduct 6 focus groups with 10 African American women in each of the following counties: Dane, Rock, Milwaukee, Kenosha, and Racine and Winnebago (IL), and (2) create and broadly distribute a survey created based on focus group learning.

Objective 1:

- Developed a moderator guide, completed IRB submission and finalized revision for last change of protocol prior to field implementation- Developed the following in partnership with the UW Survey Center:
 - Focus group moderator guide and accompanying surveys
 - Electronic focus group moderator training with companion in-person Q&A
- Hired the two community-based focus group moderators and modified IRB protocol to include them.
- Completed training of the two community-based facilitators.
- Added a MPH practicum student (an MD-MPH student between years 3 and 4 of medical school at UW, who intends to pursue Oncology) to the team to aid implementation and provide learning experience.
- Established relationships in African American communities within each of the 6 target counties.
- Identified a focus group site and host organization(s) in each of the 6 counties.
- Developed a staffing plan and dates for all 6 focus groups to be held in March and April 2018.
- Recruited 20 of 60 participants, and a waiting list exists for two counties. Recruitment process is ongoing.
- Collaborating with the UW SMPH Center for Community Engagement and Health Partnerships on outreach activities in Milwaukee, Racine and Kenosha counties.

Objective 2:

- MPH student identified and collected validated tools to guide survey development.
- Student assembling "base" survey to be informed and modified based on focus group results.
- Discussed modified methods for administration – mail based vs. in person

UW-Center for Tobacco Research and Intervention (UW-CTRI) Tobacco Cessation Academic Detailing with Wisconsin Cancer Clinics/Centers

Goal

For CY 2019, UW-CTRI committed to providing onsite, telephone, and electronic academic detailing to implement evidence-based clinical tobacco cessation interventions with cancer clinics/centers in Wisconsin. This work is in support of the University of Wisconsin Carbone Cancer Center's (UWCCC) cancer prevention and tobacco cessation efforts.

Activities for CY 2019

B. The University of Wisconsin Center for Tobacco Research and Intervention **provided tailored training and technical assistance to help the following four Cancer Clinics/Centers with integration of evidence-based tobacco cessation treatment interventions:**

- Aspirus Regional Cancer Center
- Froedtert and the Medical College of Wisconsin Cancer Center (Grand Rounds)
- Marshfield Clinic Eau Claire Cancer Center

In addition, UW-CTRI presented about tobacco cessation resources, including the Wisconsin Tobacco Quit Line, at the **UW Carbone Cancer Center 2019 Fall Conference**.

During CY 2019, UW-CTRI Outreach staff **completed 19 phone, in-person, and email training and technical assistance contacts with 268 staff at the three Cancer Clinics/Centers listed above.**

Sites differed markedly regarding their integration of evidence-based tobacco dependence treatment. Our work with all of the Clinics/Centers included:

- Determining patient visit flow; helping define and design staff and clinician roles and workflow relative to the identification of, intervention with, and documentation of patients who use tobacco.
- Providing training and technical assistance about brief, practical, evidence-based tobacco cessation interventions, including EHR modifications.

- Identifying and integrating sources of tobacco cessation treatment extenders, including in-clinic and in-community tobacco cessation resources as well as the Wisconsin Tobacco Quit Line.

Overall, the Cancer Clinics/Centers are working to make the delivery of evidence-based tobacco cessation the standard of care for all of their patients.

Report prepared by: Rob Adsit, MEd, Director of Outreach Programs, UW-CTRI, ral@ctri.wisc.edu

2020

Dr. Ruth O'Regan, lead PI for the Breast Cancer Specialized Programs of Research Excellence (SPOREs) grant

Ruth O'Regan, MD, is a Clinical PI on a recent submission for a Specialized Program of Research Excellence (SPORE) focused on addressing breast cancer. This includes a research project that expands on a previous collaborative pilot project with Dr. Kent Hoskins (University of Illinois-Chicago) to investigate mechanisms of resistance to androgen receptor (AR) signaling inhibitors (ARSIs). The central hypothesis of this project is that mechanisms of resistance to ARSIs in AR+ triple-negative breast cancer (TNBC) involve alterations in AR and AR signaling, and that this resistance can be overcome therapeutically through CDK inhibition and other approaches.

This hypothesis will be assessed through three specific aims:

Aim 1: Evaluating mechanisms of resistance in AR+ TNBC models with *de novo* and acquired ARSI resistance *in vitro* and *in vivo*.

Using a panel of AR+ TNBC cell lines with differing expression of AR and sensitivity to standard ARSIs, we will characterize AR, and correlate expression with ARSI activity. Results will be confirmed *in vivo*, including in patient-derived models of AR+ TNBC. We will evaluate whether the expression of PSMA in tumor specimens and by non-invasive PET imaging correlates with activity of ARSI *in vivo*.

Aim 2: Determining if the addition of CDKi to ARSI therapy can overcome ARSI resistance, and identifying predictive biomarkers for this approach.

Patients with AR+ metastatic TNBC will be recruited to a phase 2 clinical trial evaluating the addition of CDKi with ribociclib (RIBO) to bicalutamide (BICA), following a 2-week run in of BICA. Baseline metastatic tumor specimens and CTCs from patients recruited to the clinical trial will be assessed for AR expression, AR-Vs, PSMA and TNBC subtype and will be correlated with activity of BICA alone (decrease in Ki67) or the combination of BICA and RIBO (clinical benefit rate (CBR) at 16 weeks). Baseline PSMA expression using 18F-DCFPyL PET imaging will be correlated with change in Ki67 and CBR at 16 weeks.

Aim 3: Identifying future therapeutic approaches for AR+ TNBC.

Using AR+ TNBC preclinical models the efficacy of newer ARSIs will be evaluated and activity will be correlated with biomarkers associated with ARSI resistance. We will evaluate a theranostics approach to treating AR+ TNBC that expresses PSMA using 177Lu-PSMA TRT in preclinical models.

This research can revolutionize the treatment of AR+TNBC. First, determining which AR+TNBC are sensitive to ARSIs can allow the tailoring of these relatively non-toxic therapies to patients most likely to benefit. This could ultimately allow translation of these AR-directed agents into the early stage adjuvant setting. Second, the use of CTCs as a means of assessing the cancer in real time for presence of resistance mechanisms can allow an early determination of when and how resistance to ARSIs develops. Third, the addition of CDKi to ARSI could be an effective therapy, which if confirmed in larger trials, can allow a significantly higher percentage of patients with AR+ TNBC to benefit from these relatively non-toxic, targeted agents. Fourth, our preclinical experiments can identify other approaches for AR+TNBC that can be evaluated in future clinical trials. In summary, this research can dramatically improve outcomes for patients with AR+TNBC.

UW-Center for Tobacco Research and Intervention (UW-CTRI) Tobacco Cessation Academic Detailing with Wisconsin Cancer Clinics/Centers

Goal

For CY 2020, UW-CTRI committed to providing onsite, telephone, and electronic academic detailing to implement evidence-based clinical tobacco cessation interventions with cancer clinics/centers in Wisconsin.

This work is in support of the University of Wisconsin Carbone Cancer Center's (UWCCC) cancer prevention and tobacco cessation efforts.

Activities for CY 2020

The Covid pandemic disrupted health care for much of 2020, including cancer and oncology care.

The University of Wisconsin Center for Tobacco Research and Intervention **provided tailored training and technical assistance to help the following four Cancer Clinics/Centers with integration of evidence-based tobacco cessation treatment interventions:**

Aspirus Regional Cancer Center

**Froedtert and the Medical College of Wisconsin
Cancer Center**

Marshfield Clinic Eau Claire Cancer Center

Mercy Health System Oncology Clinic

During CY 2020, UW-CTRI Outreach staff **completed 10 phone, in-person, virtual, and email training and technical assistance contacts with 203 staff at the four Cancer Clinics/Centers listed above.**

Sites differed markedly regarding their integration of evidence-based tobacco dependence treatment. Our work with all of the Clinics/Centers included:

- Determining patient visit flow; helping define and design staff and clinician roles and workflow relative to the identification of, intervention with, and documentation of patients who use tobacco.
- Providing training and technical assistance about brief, practical, evidence-based tobacco cessation interventions, including EHR modifications.
- Identifying and integrating sources of tobacco cessation treatment extenders, including in-clinic and in-community tobacco cessation resources as well as the Wisconsin Tobacco Quit Line.

Overall, excluding the Covid pandemic, the Cancer Clinics/Centers are working to make the delivery of evidence-based tobacco cessation the standard of care for all of their patients.

Report prepared by: Rob Adsit, MEd, Director of Outreach Programs, UW-CTRI, ra1@ctri.wisc.edu

Activities for CY 2021

Goal

For CY 2021, UW-CTRI committed to providing onsite, telephone, and electronic academic detailing to implement evidence-based clinical tobacco cessation interventions with cancer clinics/centers in Wisconsin. This work is in support of the University of Wisconsin Carbone Cancer Center's (UWCCC) cancer prevention and tobacco cessation efforts.

Since the launch of the UW-CTRI Outreach Program in 2001 as part of a comprehensive, statewide tobacco control program, UW-CTRI outreach specialists have worked with virtually every healthcare system and insurer—as well as hundreds of clinics and dozens of hospitals across Wisconsin—to ensure tobacco users throughout the state have access to affordable tobacco treatment to quit smoking or chewing tobacco.

These outreach professionals have offices in Eau Claire, Oshkosh, Milwaukee, and Madison. They provide training and technical assistance to clinics, hospitals and health systems to create sustainable improvements to the way they offer tobacco treatment. It's all based on research summarized in the U.S. Public Health Service Clinical Practice Guideline: [*Treating Tobacco Use and Dependence*](#).

Calendar year 2021 funding has, in part, supported Distinguished Scientist Dr. Bruce Christiansen, who leads the Wisconsin Nicotine Treatment Integration Project ([WiNTiP](#)), which works to help behavioral health patients to

quit tobacco use. Dr. Christiansen recently published an article titled Measuring Therapeutic Alliance for Tobacco Cessation Counseling for Behavioral Health Clinicians. *Journal of Smoking Cessation*. Vol. 2021, Article ID 6671899 discussing the effectiveness of Behavioral Health Clinician's interventional efforts to help patients stop smoking.

Activities for CY 2022

Carbone Cancer Center

The University of Wisconsin Carbone Cancer Center genitourinary cancer research includes prostate cancer, which is the most common cancer in men and a source of significant morbidity and mortality (>30,000 deaths annually). Current research projects combine cutting-edge basic science discoveries with clinical (surgical, medical and radiation oncologists) expertise to exploit novel observations that will improve outcomes and quality of life for patients with this disease. Using state-of-the-art imaging, bioinformatics and novel pathology resources Carbone researchers develop and exploit new diagnostic approaches and treatments that will change the way prostate cancer is managed.

Basic scientists with prostate cancer clinicians advance treatment strategies for prostate cancer patients. The broad objectives are to: 1) Increase multidisciplinary translational research and develop the next generation of prostate cancer researchers, 2) Develop common resources to promote advances, 3) Translate promising new approaches into patients, and 4) Improve overall survival and quality of life for patients with prostate cancer. This research will advance treatments and understanding of prostate cancer and undoubtedly beneficially impact patients with this disease.

The University of Wisconsin Carbone Cancer Center breast cancer research aims to meet the needs of breast cancer patients, particularly the underserved from both rural and urban settings through translational science. Breast cancer is the second most common cancer with more than 1.7 million cases diagnosed annually worldwide. In the United States, more than 270,000 cases of invasive breast cancer were seen in 2020, with approximately 42,000 patients dying from metastatic disease annually. Mortality rates are higher in underserved populations whether they live in urban or rural settings. Targeted therapies have improved outcomes for patients with certain subtypes of breast cancer. However, therapeutic resistance is common and is the primary reason for the development of metastatic breast cancer, leading ultimately to death. Moreover, there is a need for better predictive biomarkers for traditional cytotoxic therapies to optimally select patients who are likely to benefit from these agents. Given the efficacy of targeted agents in specific breast cancer subtypes, such as HER2-positive cancers, the issue of over-treatment and resulting toxicities is an increasingly significant issue. Specific objectives and goals for breast cancer research are to 1) promote translational research in breast cancer, including integrating innovative technology, targeting a diverse patient population 2) Improve outcomes and quality of life for patients with breast cancer 3) Determine mechanisms underlying therapy resistance as a means to develop new therapeutic approaches 4) Develop common resources, including patient-derived models, to be shared within and with other institutions.

Summary of Activities for Calendar Year 2022

UW-Center for Tobacco Research and Intervention (UW-CTRI) Tobacco Cessation Academic Detailing with Wisconsin Cancer Clinics/Centers
December 2022

Goal

For CY 2022, UW-CTRI committed to providing onsite, telephone, and electronic academic detailing to implement evidence-based clinical tobacco cessation interventions with cancer clinics/centers in Wisconsin. This work is in support of the University of Wisconsin Carbone Cancer Center's (UWCCC) cancer prevention and tobacco cessation efforts.

Activities for CY 2022

The University of Wisconsin Center for Tobacco Research and Intervention Outreach Program **provided tailored training and technical assistance to help the following eight Cancer Clinics/Centers with integration of evidence-based tobacco cessation treatment interventions:**

Aspirus Regional Cancer Center

Froedtert and the Medical College of Wisconsin Cancer Center

Marshfield Clinic Eau Claire Cancer Center
Mercy Health System Oncology Clinic
Fox Valley Hematology and Oncology
Aurora Cancer Care – Wauwatosa
Marshfield Clinic Western Cancer Center
Saint Vincent Hospital Regional Cancer Center

During CY 2022, UW-CTRI Outreach staff **completed 23 phone, in-person, virtual, and email training and technical assistance contacts with 374 staff at the eight Cancer Clinics/Centers listed above.**

Sites differed markedly regarding their integration of evidence-based tobacco dependence treatment. Our work with all of the Clinics/Centers included:

- Determining patient visit flow; helping define and design staff and clinician roles and workflow relative to the identification of, intervention with, and documentation of patients who use tobacco.
- Providing training and technical assistance about brief, practical, evidence-based tobacco cessation interventions, including EHR and workflow modifications.
- Identifying and integrating sources of tobacco cessation treatment extenders, including in-clinic and in-community tobacco cessation resources as well as the Wisconsin Tobacco Quit Line.

Overall, the Cancer Clinics/Centers are working to make the delivery of evidence-based tobacco cessation the standard of care for all their patients.

Report prepared by: Rob Adsit, MEd, Director of Outreach Programs, UW-CTRI, ra1@ctri.wisc.edu

SUMMARY

Successful research in many areas will be required to realize definitive positive changes in the burden of cancer. We have already seen a decline in the number of deaths, but successful outcomes in research that addresses the causes, risks, prevention, and treatment of this disease will be required to eliminate the burden of this disease. This progress report provides a status report on how the proceeds from the Wisconsin Cancer Research Tax Check-off are currently being invested by the University of Wisconsin Carbone Cancer Center to bring us closer to the day when the burden from cancer is eliminated.

Grants Resulting From State Cancer Research Tax Check-Off

December 31, 2016

Grant	Agency	PI	Total Award	Title	Dates of Award
133-PRJ91UU	ASH	Asimakopoulos	\$150,000	The Role of TPL2 Kinase in Regulating Macrophage-Myeloma Tumor Cell Interactions	09/14/14-09/14/15
5R01CA127379-04	NIH/NCI	Burnside	\$1,079,005	Machine Learning for Improved Mammography Screening	05/01/07-03/31/12
5U01ES019466-05	NIH/NIEHS	Gould	\$2,173,274	Genetics of Breast Cancer Risk at Windows of Exposure	09/01/10-04/30/15
5R01ES017400-05	NIH/NIEHS	Gould/Newton	\$2,086,696	Breast Cancer GWAS: Function and Environmental Interactions	12/11/08-10/31/14
5R01CA123272-05	NIH/NCI	Gould	\$2,052,776	Characterizing a Breast Cancer Modifier Locus That Associates with Human Risk	07/13/06-05/31/12
W81XWH-07-1-0404	DoD/Army	Gould	\$252,059	Mechanisms Underlying the Breast Cancer Susceptibility Locus Mcs5c	07/01/07-06/30/10
W81XWH-11-1-0161	DoD/Army	Gould	\$127,040	Functional Analysis of the Rat Mammary Carcinoma Susceptibility Locus (Mcs5c)	06/01/11-06/30/14
W81XWH-12-1-0085	DoD/Army	Basu	\$111,067	Reactive Oxygen Species Produced by Prostate Cancer Cells Cause Castrate-resistant Cell Growth by	03/01/12-02/28/13

				Inducing B-Cell Lymphotoxin Release	
W81XWH-08-1-0525	DoD/Army	Alarid	\$111,375	Microfluidic Applications in Defining Regulatory Roles of the Breast Cancer Microenvironment	08/01/08-08/31/09
5R33CA160344-03	NIH/NCI	Alarid/Beebe	\$818,072	Integrated Microscale Transcriptional Profiling of Cell Communication Networks	09/12/11-08/31/15
1R01CA185251-01	NIH/NCI	Basu/Beebe/Eliceiri	\$2,868,458	[PQC-3] A Metabolic Pathway Activation Marker for Prostate Cancer Prognosis	07/01/14-05/31/18
W81XWH-09-1-0192	DoD/Army	Beebe	\$515,631	Arrayed Microchannel-based Assays for Circulating Tumor Cell Capture, Culture, and Analysis	07/01/09-07/31/13
W81XWH-11-1-0208	DoD/Army	Beebe	\$110,980	Inhibition of Breast Cancer Progression by Blocking Heterocellular Contact between Epithelial Cells and Fibroblasts	04/01/11-04/30/13
OPP1028788	Bill & Melinda Gates Foundation	Beebe	\$2,584,034	Microfluidic Phase-Gate: Simplified Sample Preparation for POC Diagnostics in the Developing World	06/27/11-12/31/14
5R33CA137673-03	NIH/NCI	Beebe	\$1,400,415	Microchannel Cell-based Assays to Enable Cancer Research	05/01/09-04/30/13
1R01EB010039-01A2	NIH/NIBIB	Beebe	\$1,742,153	Understanding Cell Migration through Microscale in Vitro Models	09/01/11-06/30/15
5R01CA155192-03	NIH/NCI	Beebe/Miyamoto	\$817,882	Enabling NF-kB Signal Transduction Studies in Primary Multiple Myeloma Cells	06/21/12-04/30/17
1R01CA181648-01A1	NIH/NCI	Lang/Berry Mentor: Beebe	\$1,552,947	VERSA: An Integrated, Multi-Endpoint Platform for Circulating Tumor Cell Analysis	04/09/14-02/28/19
W81XWH-11-1-0648	DoD/Army	Cai	\$445,454	Development of Biodegradable Zinc Oxide Nanowires Targeting Breast Cancer Metastasis	08/15/11-08/14/15
W81XWH-11-1-0644	DoD/Army	Cai	\$654,418	Molecular Imaging and Therapy of Prostate Cancer	09/26/11-09/25/15
133-PRJ56DV	Pardee Foundation	Cai	\$154,250	Novel Combination Therapy for Prostate Cancer	03/01/12-02/28/13
5R01CA169365-02	NIH/NCI	Cai	\$887,321	Novel Combination Therapy for Prostate Cancer	04/12/13-03/31/16
RSG-13-009-01-CCE	ACS	Cai	\$802,750	Imaging Biomarkers for Combination Therapy of Prostate Cancer	07/01/13-06/30/17
W81XWH-12-1-0052	DoD/Army	Lang Mentors: Beebe/McNeel	\$700,785	Physician Research Training Award: Promotion of Anti-Tumor Immune Responses with Epigenetic Modifying Agents	08/01/12-07/31/17
133-PRJ54KE	PCF	Liu/Jeraj	\$300,000	Developing a Novel Quantitative Bone Imaging (QTBI) Methodology to Assess Treatment Response in Metastatic Prostate Cancer	05/23/11-05/31/14
133-PRJ54XV	PCF	Liu	\$634,420	Imaging Biomarkers of Treatment Response using NaF PET/CT Imaging: a Prostate Cancer Clinical Trials Consortium Effort	08/03/11-08/31/15
5R03CA139548-02	NIH/NCI	Trentham-Dietz	\$147,224	The Vitamin D Pathway and Mammographic Breast Density in Postmenopausal Women	06/01/09-05/31/12
5R01CA067264-14	NIH/NCI	Trentham-Dietz	\$1,728,186	Breast Carcinoma in Situ: Predicting Risk and Outcomes	03/19/09-08/31/15
W81XWH11-1-0047	DoD/Army	Trentham-Dietz	\$74,251	Hormonal Factors and Breast Cancer Loci	01/01/11-01/31/13
W81XWH11-1-0214	DoD/Army	Trentham-Dietz	\$229,385	Tumor Microenvironment and Progression to Invasion After a	03/01/11-09/30/13

				Diagnosis of Ductal Carcinoma in Situ	
135-135GV92	WARF	Trentham-Dietz	\$33,266	Genetic Polymorphisms in Relation to Breast Cancer Survival	01/01/08-06/30/09
133-PRJ28PK	Prevent Cancer Foundation	Trentham-Dietz	\$44,463	Modifiable Risk Factors for Breast Cancer Events After Diagnosis of Ductal Carcinoma in Situ (DCIS)	07/15/09-07/14/11
5R21CA170876-02	NIH/NCI	Halberg/Schelman	\$350,252	Molecular Differences Predicting Tumor Progression in Colorectal Cancer (PQ #14)	09/01/12-08/31/14
5R01GM097245-04	NIH/NIGMS	Burkard	\$1,373,165	Separation of Late Mitotic Functions of Polo-like Kinase 1 with Chemical Genetics	09/01/11-04/30/16
IRG-58-011-48	ACS	Burkard	\$30,000	Synthetic Lethal Screen for Chemicals Targeting Polyploidy	06/0/10-05/31/12
5R01CA125387-04S1	NIH/NCI	Xu	\$94,758	Transcriptional Regulation of Estrogen Receptor (ER) by CARM1	08/01/11-01/31/13
W81XWH-11-1-0237	DoD/Army	Xu	\$3,649,454	Old Receptors, New Treatment Strategies for Breast Cancer	04/01/11-04/30/16
W81XWH-11-1-0165	DoD/Army	Xu	\$97,292	Targeting Estrogen Receptor-Beta in Triple Negative Breast Cancer	02/01/11-02/28/14
Total Amount			\$32,984,958		

Publications Generated as a result of the State Cancer Research Tax Check-Off:

1. McElroy JA, Shafer MM, Trentham-Dietz A, Hampton JM, Newcomb PA. Cadmium exposure and breast cancer risk. *J Natl Cancer Inst* 98(12):869-73, 2006.
2. Yasui Y, Newcomb PA, Trentham-Dietz A, Egan KM. Familial relative risk estimates for use in epidemiologic analyses. *Am J Epidemiol* 164(7):697-705, 2006.
3. Gaudet MM, Egan KM, Lissowska J, Newcomb PA, Brinton LA, Titus-Ernstoff L, Yeager M, Chanock S, Welch R, Peplonska B, Trentham-Dietz A, Garcia-Closas M. Genetic variation in tumor necrosis factor and lymphotoxin-alpha (TNF-LTA) and breast cancer risk. *Hum Genet* 121(3-4):483-90, 2007.
4. Liang X, Trentham-Dietz A, Titus-Ernstoff L, Newcomb PA, Welch RA, Hutchinson AA, Hampton JM, Sutcliffe CB, Haines JL, Egan KM. Whole-genome amplification of oral rinse self-collected DNA in a population-based case-control study of breast cancer. *Cancer Epidemiol Biomarkers Prev* 16(8):1610-4, 2007.
5. Samuelson DJ, Hesselson SE, Aperavich BA, Zan Y, Haag JD, Trentham-Dietz A, Hampton JM, Mau B, Chen KS, Baynes C, Khaw KT, Luben R, Perkins B, Shah M, Pharoah PD, Dunning AM, Easton DF, Ponder BA, Gould MN. Rat Mcs5a is a compound quantitative trait locus with orthologous human loci that associate with breast cancer risk. *Proc Natl Acad Sci U S A* 104(15):6299-304, 2007. PMID: PMC1847458
6. Sprague BL, Trentham-Dietz A, Garcia-Closas M, Newcomb PA, Titus-Ernstoff L, Hampton JM, Chanock SJ, Haines JL, Egan KM. Genetic variation in TP53 and risk of breast cancer in a population-based case control study. *Carcinogenesis* 28(8):1680-6, 2007.
7. Zastrow E, Davis SK, Lazebnik M, Kelcz F, Van Veen BD, Hagness SC. Development of anatomically realistic numerical breast phantoms with accurate dielectric properties for modeling microwave interactions with the human breast. *IEEE Trans Biomed Eng* 55(12):2792-800, 2008. PMID: PMC2621084
8. Gaudet MM, Milne RL, Cox A, Camp NJ, Goode EL, Humphreys MK, Dunning AM, Morrison J, Giles GG, Severi G, Baglietto L, English DR, Couch FJ, Olson JE, Wang X, Chang-Claude J, Flesch-Janys D, Abbas S, Salazar R, Mannermaa A, Kataja V, Kosma VM, Lindblom A, Margolin S, Heikkinen T, Kampjarvi K, Aaltonen K, Nevanlinna H, Bogdanova N, Coinac I, Schurmann P, Dork T, Bartram CR, Schmutzler RK, Tchatchou S, Burwinkel B, Brauch H, Torres D, Hamann U, Justenhoven C, Ribas G, Arias JI, Benitez J, Bojesen SE, Nordestgaard BG, Flyger HL, Peto J, Fletcher O, Johnson N, Dos Santos Silva I, Fasching PA, Beckmann MW, Strick R, Ekici AB, Broeks A, Schmidt MK, van Leeuwen FE, Van't Veer LJ, Southey MC, Hopper JL, Apicella C, Haiman CA, Henderson BE, Le Marchand L, Kolonel LN, Kristensen V, Grenaker Alnaes G, Hunter DJ, Kraft P, Cox DG, Hankinson SE, Seynaeve C, Vreeswijk MP, Tollenaar RA, Devilee P, Chanock S, Lissowska J, Brinton L, Peplonska B, Czene K, Hall P, Li Y,

- Liu J, Balasubramanian S, Rafii S, Reed MW, Pooley KA, Conroy D, Baynes C, Kang D, Yoo KY, Noh DY, Ahn SH, Shen CY, Wang HC, Yu JC, Wu PE, Anton-Culver H, Ziogoas A, Egan K, Newcomb P, Titus-Ernstoff L, Trentham Dietz A, Sigurdson AJ, Alexander BH, Bhatti P, Allen-Brady K, Cannon-Albright LA, Wong J, Chenevix-Trench G, Spurdle AB, Beesley J, Pharoah PD, Easton DF, Garcia-Closas M. Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium. *Cancer Epidemiol Biomarkers Prev* 18(5):1610-6, 2009. PMID: PMC2737177
9. Gould MN. The utility of comparative genetics to inform breast cancer prevention strategies. *Genetics* 183(2):409-12, 2009. PMID: PMC2766305
 10. Huang Y, Trentham-Dietz A, Garcia-Closas M, Newcomb PA, Titus-Ernstoff L, Hampton JM, Chanock SJ, Haines JL, Egan KM. Association of CYP1B1 haplotypes and breast cancer risk in Caucasian women. *Cancer Epidemiol Biomarkers Prev* 18(4):1321-3, 2009. PMID: PMC2692636
 11. Johnson BL, Trentham-Dietz A, Koltyn KF, Colbert LH. Physical activity and function in older, long-term colorectal cancer survivors. *Cancer Causes Control* 20(5):775-84, 2009. PMID: PMC2716661
 12. Mignone LI, Giovannucci E, Newcomb PA, Titus-Ernstoff L, Trentham-Dietz A, Hampton JM, Orav EJ, Willett WC, Egan KM. Meat consumption, heterocyclic amines, NAT2, and the risk of breast cancer. *Nutr Cancer* 61(1):36-46, 2009.
 13. Moran CJ, Kelcz F, Jung Y, Brodsky EK, Fain SB, Block WF. Pilot study of improved lesion characterization in breast MRI using a 3D radial balanced SSFP technique with isotropic resolution and efficient fat-water separation. *J Magn Reson Imaging* 30(1):135-44, 2009. PMID: PMC3743726
 14. Nichols HB, Trentham-Dietz A, Egan KM, Titus-Ernstoff L, Holmes MD, Bersch AJ, Holick CN, Hampton JM, Stampfer MJ, Willett WC, Newcomb PA. Body mass index before and after breast cancer diagnosis: associations with all-cause, breast cancer, and cardiovascular disease mortality. *Cancer Epidemiol Biomarkers Prev* 18(5):1403-9, 2009. PMID: PMC2715918
 15. Smits BM, Gould MN. "Gene targeting in the rat? Cut it out!". *Mol Interv* 9(5):226-9, 2009.
 16. Sprague BL, Trentham-Dietz A. Prevalence of breast carcinoma in situ in the United States. *Jama* 302(8):846-8, 2009. PMID: PMC2884369
 17. Sung KE, Su G, Pehlke C, Trier SM, Eliceiri KW, Keely PJ, Friedl A, Beebe DJ. Control of 3-dimensional collagen matrix polymerization for reproducible human mammary fibroblast cell culture in microfluidic devices. *Biomaterials* 30(27):4833-41, 2009. PMID: PMC2865186
 18. Trentham-Dietz A. Epidemiologic breast cancer research at the UW-Madison: a summary of past accomplishments and future directions. *Wmj* 108(5):284-5, 2009.
 19. Woditschka S, Haag JD, Sullivan R, Gould MN. A short-term rat mammary carcinogenesis model for the prevention of hormonally responsive and nonresponsive in situ carcinomas. *Cancer Prev Res (Phila)* 2(2):153-60, 2009. PMID: PMC2881640
 20. Anic GM, Titus-Ernstoff L, Newcomb PA, Trentham-Dietz A, Egan KM. Sleep duration and obesity in a population-based study. *Sleep Med* 11(5):447-51, 2010. PMID: PMC2854876
 21. Bauer M, Su G, Beebe DJ, Friedl A. 3D microchannel co-culture: method and biological validation. *Integr Biol (Camb)* 2(7-8):371-8, 2010. PMID: PMC3025353
 22. Berthier E, Surfus J, Verbsky J, Huttenlocher A, Beebe D. An arrayed high-content chemotaxis assay for patient diagnosis. *Integr Biol (Camb)* 2(11-12):630-8, 2010.
 23. Burkard ME, Jallepalli PV. Validating cancer drug targets through chemical genetics. *Biochim Biophys Acta* 1806(2):251-7, 2010. PMID: PMC3028588
 24. Charoensuksai P, Xu W. PPARs in Rhythmic Metabolic Regulation and Implications in Health and Disease. *PPAR Res* 2010, 2010. PMID: PMC2943104
 25. Huang SX, Powell E, Rajski SR, Zhao LX, Jiang CL, Duan Y, Xu W, Shen B. Discovery and total synthesis of a new estrogen receptor heterodimerizing actinopolymorphol A from *Actinopolymorpha rutilus*. *Org Lett* 12(15):3525-7, 2010. PMID: PMC2913291
 26. Ju J, Warrick J, Beebe DJ. A Cell Programmable Assay (CPA) chip. *Lab Chip* 10(16):2071-6, 2010.
 27. Ng CS, Raunig DL, Jackson EF, Ashton EA, Kelcz F, Kim KB, Kurzrock R, McShane TM. Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses. *AJR Am J Roentgenol* 194(2):W134-40, 2010.

28. Paguirigan AL, Puccinelli JP, Su X, Beebe DJ. Expanding the available assays: adapting and validating In-Cell Westerns in microfluidic devices for cell-based assays. *Assay Drug Dev Technol* 8(5):591-601, 2010. PMID: PMC2957247
29. Peterson NB, Trentham-Dietz A, Garcia-Closas M, Newcomb PA, Titus-Ernstoff L, Huang Y, Chanock SJ, Haines JL, Egan KM. Association of COMT haplotypes and breast cancer risk in Caucasian women. *Anticancer Res* 30(1):217-20, 2010. PMID: PMC3086748
30. Powell E, Huang SX, Xu Y, Rajski SR, Wang Y, Peters N, Guo S, Xu HE, Hoffmann FM, Shen B, Xu W. Identification and characterization of a novel estrogenic ligand actinopolymorphol A. *Biochem Pharmacol* 80(8):1221-9, 2010. PMID: PMC2934894
31. Powell E, Wang Y, Shapiro DJ, Xu W. Differential requirements of Hsp90 and DNA for the formation of estrogen receptor homodimers and heterodimers. *J Biol Chem* 285(21):16125-34, 2010. PMID: PMC2871481
32. Puccinelli JP, Su X, Beebe DJ. Automated high-throughput microchannel assays for cell biology: Operational optimization and characterization. *JALA Charlottesville Va* 15(1):25-32, 2010. PMID: PMC2830798
33. Shanle EK, Xu W. Selectively targeting estrogen receptors for cancer treatment. *Adv Drug Deliv Rev* 62(13):1265-76, 2010. PMID: PMC2991615
34. Sprague BL, Trentham-Dietz A, Burnside ES. Socioeconomic disparities in the decline in invasive breast cancer incidence. *Breast Cancer Res Treat* 122(3):873-8, 2010. PMID: PMC2904433
35. Sprague BL, Trentham-Dietz A, Nichols HB, Hampton JM, Newcomb PA. Change in lifestyle behaviors and medication use after a diagnosis of ductal carcinoma in situ. *Breast Cancer Res Treat* 124(2):487-95, 2010. PMID: PMC2924938
36. van Boxtel R, Gould MN, Cuppen E, Smits BM. ENU mutagenesis to generate genetically modified rat models. *Methods Mol Biol* 597:151-67, 2010.
37. Warrick J, Casavant B, Frisk M, Beebe D. A microfluidic cell concentrator. *Anal Chem* 82(19):8320-6, 2010. PMID: PMC3074536
38. Young EW, Beebe DJ. Fundamentals of microfluidic cell culture in controlled microenvironments. *Chem Soc Rev* 39(3):1036-48, 2010. PMID: PMC2967183
39. Al-Dhaheri M, Wu J, Skliris GP, Li J, Higashimoto K, Wang Y, White KP, Lambert P, Zhu Y, Murphy L, Xu W. CARM1 is an important determinant of ERalpha-dependent breast cancer cell differentiation and proliferation in breast cancer cells. *Cancer Res* 71(6):2118-28, 2011. PMID: PMC3076802
40. Berry SM, Alarid ET, Beebe DJ. One-step purification of nucleic acid for gene expression analysis via Immiscible Filtration Assisted by Surface Tension (IFAST). *Lab Chip* 11(10):1747-53, 2011. PMID: PMC3244820
41. Berry SM, Strotman LN, Kueck JD, Alarid ET, Beebe DJ. Purification of cell subpopulations via immiscible filtration assisted by surface tension (IFAST). *Biomed Microdevices* 13(6):1033-42, 2011. PMID: PMC3314424
42. Berthier E, Warrick J, Casavant B, Beebe DJ. Pipette-friendly laminar flow patterning for cell-based assays. *Lab Chip* 11(12):2060-5, 2011. PMID: PMC3401607
43. Cai Q, Wen W, Qu S, Li G, Egan KM, Chen K, Deming SL, Shen H, Shen CY, Gammon MD, Blot WJ, Matsuo K, Haiman CA, Khoo US, Iwasaki M, Santella RM, Zhang L, Fair AM, Hu Z, Wu PE, Signorello LB, Titus-Ernstoff L, Tajima K, Henderson BE, Chan KY, Kasuga Y, Newcomb PA, Zheng H, Cui Y, Wang F, Shieh YL, Iwata H, Le Marchand L, Chan SY, Shrubsole MJ, Trentham-Dietz A, Tsugane S, Garcia-Closas M, Long J, Li C, Shi J, Huang B, Xiang YB, Gao YT, Lu W, Shu XO, Zheng W. Replication and functional genomic analyses of the breast cancer susceptibility locus at 6q25.1 generalize its importance in women of Chinese, Japanese, and European ancestry. *Cancer Res* 71(4):1344-55, 2011. PMID: PMC3083305
44. Cai W. Aptamers: versatile agents for biomedical applications. *Curr Med Chem* 18(27):4106, 2011.
45. Cai W, Hong H. Peptoid and Positron Emission Tomography: an Appealing Combination. *Am J Nucl Med Mol Imaging* 1(1):76-9, 2011. PMID: PMC3183479
46. Cai W, Zhang Y, Kamp TJ. Imaging of Induced Pluripotent Stem Cells: From Cellular Reprogramming to Transplantation. *Am J Nucl Med Mol Imaging* 1(1):18-28, 2011. PMID: PMC3155258

47. Cavnar PJ, Berthier E, Beebe DJ, Huttenlocher A. Hax1 regulates neutrophil adhesion and motility through RhoA. *J Cell Biol* 193(3):465-73, 2011. PMID: PMC3087009
48. Figueroa JD, Garcia-Closas M, Humphreys M, Platte R, Hopper JL, Southey MC, Apicella C, Hammet F, Schmidt MK, Broeks A, Tollenaar RA, Van't Veer LJ, Fasching PA, Beckmann MW, Ekici AB, Strick R, Peto J, dos Santos Silva I, Fletcher O, Johnson N, Sawyer E, Tomlinson I, Kerin M, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Bojesen S, Flyger H, Nordestgaard BG, Benitez J, Milne RL, Ignacio Arias J, Zamora MP, Brenner H, Muller H, Arndt V, Rahman N, Turnbull C, Seal S, Renwick A, Brauch H, Justenhoven C, Bruning T, Chang-Claude J, Hein R, Wang-Gohrke S, Dork T, Schurmann P, Bremer M, Hillemanns P, Nevanlinna H, Heikkinen T, Aittomaki K, Blomqvist C, Bogdanova N, Antonenkova N, Rogov YI, Karstens JH, Bermisheva M, Prokofieva D, Gantsev SH, Khusnutdinova E, Lindblom A, Margolin S, Chenevix-Trench G, Beesley J, Chen X, Mannermaa A, Kosma VM, Soini Y, Kataja V, Lambrechts D, Yesilyurt BT, Chrisiaens MR, Peeters S, Radice P, Peterlongo P, Manoukian S, Barile M, Couch F, Lee AM, Diasio R, Wang X, Giles GG, Severi G, Baglietto L, Maclean C, Offit K, Robson M, Joseph V, Gaudet M, John EM, Winqvist R, Pylkas K, Jukkola-Vuorinen A, Grip M, Andrulis I, Knight JA, Mulligan AM, O'Malley FP, Brinton LA, Sherman ME, Lissowska J, Chanock SJ, Hooning M, Martens JW, van den Ouweland AM, Collee JM, Hall P, Czene K, Cox A, Brock IW, Reed MW, Cross SS, Pharoah P, Dunning AM, Kang D, Yoo KY, Noh DY, Ahn SH, Jakubowska A, Lubinski J, Jaworska K, Durda K, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Shen CY, Ding SL, Hsu HM, Yu JC, Anton-Culver H, Ziogas A, Ashworth A, Swerdlow A, Jones M, Orr N, Trentham-Dietz A, Egan K, Newcomb P, Titus-Ernstoff L, Easton D, Spurdle AB. Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. *Hum Mol Genet* 20(23):4693-706, 2011. PMID: PMC3209823
49. Fleming ST, Sabatino SA, Kimmick G, Cress R, Wu XC, Trentham-Dietz A, Huang B, Hwang W, Liff J. Developing a claim-based version of the ACE-27 comorbidity index: a comparison with medical record review. *Med Care* 49(8):752-60, 2011.
50. German RR, Wike JM, Bauer KR, Fleming ST, Trentham-Dietz A, Namiak M, Almon L, Knight K, Perkins C. Quality of cancer registry data: findings from CDC-NPCR's Breast and Prostate Cancer Data Quality and Patterns of Care Study. *J Registry Manag* 38(2):75-86, 2011.
51. Higginbotham KS, Breyer JP, Bradley KM, Schuyler PA, Plummer WD, Jr., Freudenthal ME, Trentham-Dietz A, Newcomb PA, Sanders ME, Page DL, Parl FF, Egan KM, Dupont WD, Smith JR. A multistage association study identifies a breast cancer genetic locus at NCOA7. *Cancer Res* 71(11):3881-8, 2011. PMID: PMC3137260
52. Hong H, Benink HA, Zhang Y, Yang Y, Uyeda HT, Engle JW, Severin GW, McDougall MG, Barnhart TE, Klaubert DH, Nickles RJ, Fan F, Cai W. HaloTag: a novel reporter gene for positron emission tomography. *Am J Transl Res* 3(4):392-403, 2011. PMID: PMC3158741
53. Hong H, Goel S, Zhang Y, Cai W. Molecular imaging with nucleic acid aptamers. *Curr Med Chem* 18(27):4195-205, 2011. PMID: PMC3205285
54. Hong H, Shi J, Yang Y, Zhang Y, Engle JW, Nickles RJ, Wang X, Cai W. Cancer-targeted optical imaging with fluorescent zinc oxide nanowires. *Nano Lett* 11(9):3744-50, 2011. PMID: PMC3173586
55. Hong H, Yang Y, Zhang Y, Engle JW, Barnhart TE, Nickles RJ, Leigh BR, Cai W. Positron emission tomography imaging of CD105 expression during tumor angiogenesis. *Eur J Nucl Med Mol Imaging* 38(7):1335-43, 2011. PMID: PMC3105181
56. Kuhn P, Chumanov R, Wang Y, Ge Y, Burgess RR, Xu W. Automethylation of CARM1 allows coupling of transcription and mRNA splicing. *Nucleic Acids Res* 39(7):2717-26, 2011. PMID: PMC3074151
57. Mandelblatt JS, Stout N, Trentham-Dietz A. To screen or not to screen women in their 40s for breast cancer: is personalized risk-based screening the answer? *Ann Intern Med* 155(1):58-60, 2011.
58. Montanez-Sauri SI, Sung KE, Puccinelli JP, Pehlke C, Beebe DJ. Automation of three-dimensional cell culture in arrayed microfluidic devices. *J Lab Autom* 16(3):171-85, 2011. PMID: PMC3104941
59. Nichols HB, Visvanathan K, Newcomb PA, Hampton JM, Egan KM, Titus-Ernstoff L, Trentham-Dietz A. Bilateral oophorectomy in relation to risk of postmenopausal breast cancer: confounding by nonmalignant indications for surgery? *Am J Epidemiol* 173(10):1111-20, 2011. PMID: PMC3105288

60. Shanle EK, Hawse JR, Xu W. Generation of stable reporter breast cancer cell lines for the identification of ER subtype selective ligands. *Biochem Pharmacol* 82(12):1940-9, 2011. PMID: PMC3210412
61. Shanle EK, Xu W. Endocrine disrupting chemicals targeting estrogen receptor signaling: identification and mechanisms of action. *Chem Res Toxicol* 24(1):6-19, 2011. PMID: PMC3119362
62. Sharma D, Smits BM, Eichelberg MR, Meilahn AL, Muelbl MJ, Haag JD, Gould MN. Quantification of epithelial cell differentiation in mammary glands and carcinomas from DMBA- and MNU-exposed rats. *PLoS One* 6(10):e26145, 2011. PMID: PMC3192144
63. Shi J, Hong H, Ding Y, Yang Y, Cai W, Wang X. Evolution of Zinc Oxide Nanostructures through Kinetics Control. *J Mater Chem* 21(25):9000-8, 2011. PMID: PMC3130520
64. Smits BM, Sharma D, Samuelson DJ, Woditschka S, Mau B, Haag JD, Gould MN. The non-protein coding breast cancer susceptibility locus *Mcs5a* acts in a non-mammary cell-autonomous fashion through the immune system and modulates T-cell homeostasis and functions. *Breast Cancer Res* 13(4):R81, 2011. PMID: PMC3236344
65. Sprague BL, Trentham-Dietz A, Gangnon RE, Buist DS, Burnside ES, Bowles EJ, Stanczyk FZ, Sisney GS. Circulating sex hormones and mammographic breast density among postmenopausal women. *Horm Cancer* 2(1):62-72, 2011. PMID: PMC3035325
66. Sprague BL, Trentham-Dietz A, Remington PL. The contribution of postmenopausal hormone use cessation to the declining incidence of breast cancer. *Cancer Causes Control* 22(1):125-34, 2011. PMID: PMC3034386
67. Sung KE, Yang N, Pehlke C, Keely PJ, Eliceiri KW, Friedl A, Beebe DJ. Transition to invasion in breast cancer: a microfluidic in vitro model enables examination of spatial and temporal effects. *Integr Biol (Camb)* 3(4):439-50, 2011. PMID: PMC3094750
68. Veillet AL, Haag JD, Remfert JL, Meilahn AL, Samuelson DJ, Gould MN. *Mcs5c*: a mammary carcinoma susceptibility locus located in a gene desert that associates with tenascin C expression. *Cancer Prev Res (Phila)* 4(1):97-106, 2011. PMID: PMC3447625
69. Walsh MC, Trentham-Dietz A, Palta M. Availability of driver's license master lists for use in government-sponsored public health research. *Am J Epidemiol* 173(12):1414-8, 2011. PMID: PMC3108090
70. Wang P, Yang Y, Hong H, Zhang Y, Cai W, Fang D. Aptamers as therapeutics in cardiovascular diseases. *Curr Med Chem* 18(27):4169-74, 2011. PMID: PMC3205281
71. Wang RE, Zhang Y, Cai J, Cai W, Gao T. Aptamer-based fluorescent biosensors. *Curr Med Chem* 18(27):4175-84, 2011. PMID: PMC3205236
72. Yang Y, Zhang Y, Hong H, Liu G, Leigh BR, Cai W. In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis. *Eur J Nucl Med Mol Imaging* 38(11):2066-76, 2011. PMID: PMC3189267
73. Young EW, Berthier E, Guckenberger DJ, Sackmann E, Lamers C, Meyvantsson I, Huttenlocher A, Beebe DJ. Rapid prototyping of arrayed microfluidic systems in polystyrene for cell-based assays. *Anal Chem* 83(4):1408-17, 2011. PMID: PMC3052265
74. Zhang Y, Hong H, Cai W. Photoacoustic imaging. *Cold Spring Harb Protoc* 2011(9), 2011. PMID: PMC4167744
75. Zhang Y, Hong H, Cai W. PET tracers based on Zirconium-89. *Curr Radiopharm* 4(2):131-9, 2011. PMID: PMC3246366
76. Zhang Y, Hong H, Cai W. Tumor-targeted drug delivery with aptamers. *Curr Med Chem* 18(27):4185-94, 2011. PMID: PMC3205327
77. Zhang Y, Hong H, Engle JW, Bean J, Yang Y, Leigh BR, Barnhart TE, Cai W. Positron emission tomography imaging of CD105 expression with a ⁶⁴Cu-labeled monoclonal antibody: NOTA is superior to DOTA. *PLoS One* 6(12):e28005, 2011. PMID: PMC3235104
78. Zhang Y, Hong H, Myklejord DV, Cai W. Molecular imaging with SERS-active nanoparticles. *Small* 7(23):3261-9, 2011. PMID: PMC3228876
79. Zhang Y, Yang Y, Cai W. Multimodality Imaging of Integrin $\alpha(v)\beta(3)$ Expression. *Theranostics* 1:135-48, 2011. PMID: PMC3086621
80. Zhang Y, Yang Y, Hong H, Cai W. Multimodality molecular imaging of CD105 (Endoglin) expression. *Int J Clin Exp Med* 4(1):32-42, 2011. PMID: PMC3048982

81. Berry SM, Maccoux LJ, Beebe DJ. Streamlining immunoassays with immiscible filtrations assisted by surface tension. *Anal Chem* 84(13):5518-23, 2012.
82. Bischel LL, Lee SH, Beebe DJ. A practical method for patterning lumens through ECM hydrogels via viscous finger patterning. *J Lab Autom* 17(2):96-103, 2012. PMID: PMC3397721
83. Burkard ME, Santamaria A, Jallepalli PV. Enabling and disabling polo-like kinase 1 inhibition through chemical genetics. *ACS Chem Biol* 7(6):978-81, 2012. PMID: PMC3376236
84. Cavnar PJ, Mogen K, Berthier E, Beebe DJ, Huttenlocher A. The actin regulatory protein HS1 interacts with Arp2/3 and mediates efficient neutrophil chemotaxis. *J Biol Chem* 287(30):25466-77, 2012. PMID: PMC3408136
85. Domenech M, Bjerregaard R, Bushman W, Beebe DJ. Hedgehog signaling in myofibroblasts directly promotes prostate tumor cell growth. *Integr Biol (Camb)* 4(2):142-52, 2012. PMID: PMC3335396
86. Drinkwater NR, Gould MN. The long path from QTL to gene. *PLoS Genet* 8(9):e1002975, 2012. PMID: PMC3462162
87. Fleming ST, Kimmick GG, Sabatino SA, Cress RD, Wu XC, Trentham-Dietz A, Huang B, Hwang W, Liff JM. Defining care provided for breast cancer based on medical record review or Medicare claims: information from the Centers for Disease Control and Prevention Patterns of Care Study. *Ann Epidemiol* 22(11):807-13, 2012.
88. Frydrychowicz A, Jedynek AR, Kelcz F, Nagle SK, Reeder SB. Gadoteric acid-enhanced T1-weighted MR cholangiography in primary sclerosing cholangitis. *J Magn Reson Imaging* 36(3):632-40, 2012. PMID: PMC3419782
89. Goel S, Chin EN, Fakhraldeen SA, Berry SM, Beebe DJ, Alexander CM. Both LRP5 and LRP6 receptors are required to respond to physiological Wnt ligands in mammary epithelial cells and fibroblasts. *J Biol Chem* 287(20):16454-66, 2012. PMID: PMC3351289
90. Guckenberger DJ, Berthier E, Young EW, Beebe DJ. Induced hydrophobic recovery of oxygen plasma-treated surfaces. *Lab Chip* 12(13):2317-21, 2012. PMID: PMC4018413
91. Hein R, Maranian M, Hopper JL, Kapuscinski MK, Southey MC, Park DJ, Schmidt MK, Broeks A, Hogervorst FB, Bueno-de-Mesquita HB, Muir KR, Lophatananon A, Rattanamongkongul S, Puttawibul P, Fasching PA, Hein A, Ekici AB, Beckmann MW, Fletcher O, Johnson N, dos Santos Silva I, Peto J, Sawyer E, Tomlinson I, Kerin M, Miller N, Marmee F, Schneeweiss A, Sohn C, Burwinkel B, Guenel P, Cordina-Duverger E, Menegaux F, Truong T, Bojesen SE, Nordestgaard BG, Flyger H, Milne RL, Perez JJ, Zamora MP, Benitez J, Anton-Culver H, Ziogas A, Bernstein L, Clarke CA, Brenner H, Muller H, Arndt V, Stegmaier C, Rahman N, Seal S, Turnbull C, Renwick A, Meindl A, Schott S, Bartram CR, Schmutzler RK, Brauch H, Hamann U, Ko YD, Wang-Gohrke S, Dork T, Schurmann P, Karstens JH, Hillemanns P, Nevanlinna H, Heikkinen T, Aittomaki K, Blomqvist C, Bogdanova NV, Zalutsky IV, Antonenkova NN, Bermisheva M, Prokovieva D, Farahtdinova A, Khusnutdinova E, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma VM, Hartikainen J, Chen X, Beesley J, Lambrechts D, Zhao H, Neven P, Wildiers H, Nickels S, Flesch-Janys D, Radice P, Peterlongo P, Manoukian S, Barile M, Couch FJ, Olson JE, Wang X, Fredericksen Z, Giles GG, Baglietto L, McLean CA, Severi G, Offit K, Robson M, Gaudet MM, Vijai J, Alnaes GG, Kristensen V, Borresen-Dale AL, John EM, Miron A, Winqvist R, Pylkas K, Jukkola-Vuorinen A, Grip M, Andrulis IL, Knight JA, Glendon G, Mulligan AM, Figueroa JD, Garcia-Closas M, Lissowska J, Sherman ME, Hooning M, Martens JW, Seynaeve C, Collee M, Hall P, Humpreys K, Czene K, Liu J, Cox A, Brock IW, Cross SS, Reed MW, Ahmed S, Ghousaini M, Pharoah PD, Kang D, Yoo KY, Noh DY, Jakubowska A, Jaworska K, Durda K, Zlowocka E, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Shen CY, Yu JC, Hsu HM, Hou MF, Orr N, Schoemaker M, Ashworth A, Swerdlow A, Trentham-Dietz A, Newcomb PA, Titus L, Egan KM, Chenevix-Trench G, Antoniou AC, Humphreys MK, Morrison J, Chang-Claude J, Easton DF, Dunning AM. Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). *PLoS One* 7(8):e42380, 2012. PMID: PMC3413660
92. Higginbotham KS, Breyer JP, McReynolds KM, Bradley KM, Schuyler PA, Plummer WD, Freudenthal ME, Trentham-Dietz A, Newcomb PA, Parl FF, Sanders ME, Page DL, Egan KM, Dupont WD, Smith JR. A multistage genetic association study identifies breast cancer risk loci at 10q25 and 16q24. *Cancer Epidemiol Biomarkers Prev* 21(9):1565-73, 2012. PMID: PMC3707501

93. Hong H, Severin GW, Yang Y, Engle JW, Zhang Y, Barnhart TE, Liu G, Leigh BR, Nickles RJ, Cai W. Positron emission tomography imaging of CD105 expression with ⁸⁹Zr-Df-TRC105. *Eur J Nucl Med Mol Imaging* 39(1):138-48, 2012. PMID: PMC3228902
94. Hong H, Zhang Y, Severin GW, Yang Y, Engle JW, Niu G, Nickles RJ, Chen X, Leigh BR, Barnhart TE, Cai W. Multimodality imaging of breast cancer experimental lung metastasis with bioluminescence and a monoclonal antibody dual-labeled with ⁸⁹Zr and IRDye 800CW. *Mol Pharm* 9(8):2339-49, 2012. PMID: PMC3500677
95. Kelcz F. Wish list for future features of breast MRI computer aided evaluation. *Eur J Radiol* 81 Suppl 1:S78-9, 2012.
96. Lang JM, Casavant BP, Beebe DJ. Circulating tumor cells: getting more from less. *Sci Transl Med* 4(141):141ps13, 2012.
97. Lera RF, Burkard ME. The final link: tapping the power of chemical genetics to connect the molecular and biologic functions of mitotic protein kinases. *Molecules* 17(10):12172-86, 2012. PMID: PMC3620603
98. Mezrich JD, Nguyen LP, Kennedy G, Nukaya M, Fechner JH, Zhang X, Xing Y, Bradfield CA. SU5416, a VEGF receptor inhibitor and ligand of the AHR, represents a new alternative for immunomodulation. *PLoS One* 7(9):e44547, 2012. PMID: PMC3435281
99. Pirone JR, D'Arcy M, Stewart DA, Hines WC, Johnson M, Gould MN, Yaswen P, Jerry DJ, Smith Schneider S, Troester MA. Age-associated gene expression in normal breast tissue mirrors qualitative age-at-incidence patterns for breast cancer. *Cancer Epidemiol Biomarkers Prev* 21(10):1735-44, 2012. PMID: PMC3684707
100. Powell E, Shanle E, Brinkman A, Li J, Keles S, Wisinski KB, Huang W, Xu W. Identification of estrogen receptor dimer selective ligands reveals growth-inhibitory effects on cells that co-express ERalpha and ERbeta. *PLoS One* 7(2):e30993, 2012. PMID: PMC3274540
101. Resto PJ, Berthier E, Beebe DJ, Williams JC. An inertia enhanced passive pumping mechanism for fluid flow in microfluidic devices. *Lab Chip* 12(12):2221-8, 2012.
102. Sackmann EK, Berthier E, Young EW, Shelef MA, Wernimont SA, Huttenlocher A, Beebe DJ. Microfluidic kit-on-a-lid: a versatile platform for neutrophil chemotaxis assays. *Blood* 120(14):e45-53, 2012. PMID: PMC3466974
103. Schumacher JR, Witt WP, Palta M, Loconte NK, Heidrich SM, Trentham-Dietz A, Pandhi N, Smith MA. Cancer screening of long-term cancer survivors. *J Am Board Fam Med* 25(4):460-9, 2012. PMID: PMC3506256
104. Sharma D, Eichelberg MR, Haag JD, Meilahn AL, Muelbl MJ, Schell K, Smits BM, Gould MN. Effective flow cytometric phenotyping of cells using minimal amounts of antibody. *Biotechniques* 53(1):57-60, 2012. PMID: PMC3523330
105. Smits BM, Traun BD, Devries TL, Tran A, Samuelson D, Haag JD, Gould M. An insulator loop resides between the synthetically interacting elements of the human/rat conserved breast cancer susceptibility locus MCS5A/Mcs5a. *Nucleic Acids Res* 40(1):132-47, 2012. PMID: PMC3245909
106. Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. *Obstet Gynecol* 120(3):595-603, 2012. PMID: PMC3607288
107. Strotman LN, Lin G, Berry SM, Johnson EA, Beebe DJ. Facile and rapid DNA extraction and purification from food matrices using IFAST (immiscible filtration assisted by surface tension). *Analyst* 137(17):4023-8, 2012.
108. Su G, Sung KE, Beebe DJ, Friedl A. Functional screen of paracrine signals in breast carcinoma fibroblasts. *PLoS One* 7(10):e46685, 2012. PMID: PMC3466317
109. van Ravesteyn NT, Miglioretti DL, Stout NK, Lee SJ, Schechter CB, Buist DS, Huang H, Heijnsdijk EA, Trentham-Dietz A, Alagoz O, Near AM, Kerlikowske K, Nelson HD, Mandelblatt JS, de Koning HJ. Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk. *Ann Intern Med* 156(9):609-17, 2012. PMID: PMC3520058
110. Wu XC, Lund MJ, Kimmick GG, Richardson LC, Sabatino SA, Chen VW, Fleming ST, Morris CR, Huang B, Trentham-Dietz A, Lipscomb J. Influence of race, insurance, socioeconomic status, and hospital type on

- receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. *J Clin Oncol* 30(2):142-50, 2012.
111. Xiao Y, Hong H, Matson VZ, Javadi A, Xu W, Yang Y, Zhang Y, Engle JW, Nickles RJ, Cai W, Steeber DA, Gong S. Gold Nanorods Conjugated with Doxorubicin and cRGD for Combined Anticancer Drug Delivery and PET Imaging. *Theranostics* 2(8):757-68, 2012. PMID: PMC3425121
112. Xing Y, Nukaya M, Satyshur KA, Jiang L, Stanevich V, Korkmaz EN, Burdette L, Kennedy GD, Cui Q, Bradfield CA. Identification of the Ah-receptor structural determinants for ligand preferences. *Toxicol Sci* 129(1):86-97, 2012. PMID: PMC3491955
113. Young EW, Pak C, Kahl BS, Yang DT, Callander NS, Miyamoto S, Beebe DJ. Microscale functional cytomics for studying hematologic cancers. *Blood* 119(10):e76-85, 2012. PMID: PMC3311264
114. Andersen SW, Trentham-Dietz A, Figueroa JD, Titus LJ, Cai Q, Long J, Hampton JM, Egan KM, Newcomb PA. Breast cancer susceptibility associated with rs1219648 (fibroblast growth factor receptor 2) and postmenopausal hormone therapy use in a population-based United States study. *Menopause* 20(3):354-8, 2013. PMID: PMC3549049
115. Batina NG, Trentham-Dietz A, Gangnon RE, Sprague BL, Rosenberg MA, Stout NK, Fryback DG, Alagoz O. Variation in tumor natural history contributes to racial disparities in breast cancer stage at diagnosis. *Breast Cancer Res Treat* 138(2):519-28, 2013. PMID: PMC3610865
116. Beebe DJ, Lang JM. Editorial for "methods for the isolation and analysis of rare cells". *Methods* 64(2):101, 2013.
117. Berry SM, Regehr KJ, Casavant BP, Beebe DJ. Automated operation of immiscible filtration assisted by surface tension (IFAST) arrays for streamlined analyte isolation. *J Lab Autom* 18(3):206-11, 2013. PMID: PMC3633642
118. Berthier E, Guckenberger DJ, Cavnar P, Huttenlocher A, Keller NP, Beebe DJ. Kit-On-A-Lid-Assays for accessible self-contained cell assays. *Lab Chip* 13(3):424-31, 2013. PMID: PMC3562598
119. Bischel LL, Young EW, Mader BR, Beebe DJ. Tubeless microfluidic angiogenesis assay with three-dimensional endothelial-lined microvessels. *Biomaterials* 34(5):1471-7, 2013. PMID: PMC3529167
120. Casavant BP, Berthier E, Theberge AB, Berthier J, Montanez-Sauri SI, Bischel LL, Brakke K, Hedman CJ, Bushman W, Keller NP, Beebe DJ. Suspended microfluidics. *Proc Natl Acad Sci U S A* 110(25):10111-6, 2013. PMID: PMC3690848
121. Casavant BP, Guckenberger DJ, Berry SM, Tokar JT, Lang JM, Beebe DJ. The VerIFAST: an integrated method for cell isolation and extracellular/intracellular staining. *Lab Chip* 13(3):391-6, 2013.
122. Casavant BP, Mosher R, Warrick JW, Maccoux LJ, Berry SM, Becker JT, Chen V, Lang JM, McNeel DG, Beebe DJ. A negative selection methodology using a microfluidic platform for the isolation and enumeration of circulating tumor cells. *Methods* 64(2):137-43, 2013. PMID: PMC3858973
123. Howard AL, Pezzi HM, Beebe DJ, Berry SM. Exclusion-Based Capture and Enumeration of CD4+ T Cells from Whole Blood for Low-Resource Settings. *J Lab Autom* 19(3):313-21, 2013.
124. Lang JD, Berry SM, Powers GL, Beebe DJ, Alarid ET. Hormonally responsive breast cancer cells in a microfluidic co-culture model as a sensor of microenvironmental activity. *Integr Biol (Camb)* 5(5):807-16, 2013. PMID: PMC3648339
125. Montanez-Sauri SI, Sung KE, Berthier E, Beebe DJ. Enabling screening in 3D microenvironments: probing matrix and stromal effects on the morphology and proliferation of T47D breast carcinoma cells. *Integr Biol (Camb)* 5(3):631-40, 2013. PMID: PMC3613432
126. Moussavi-Harami SF, Annis DS, Ma W, Berry SM, Coughlin EE, Strotman LN, Maurer LM, Westphall MS, Coon JJ, Mosher DF, Beebe DJ. Characterization of molecules binding to the 70K N-terminal region of fibronectin by IFAST purification coupled with mass spectrometry. *J Proteome Res* 12(7):3393-404, 2013. PMID: PMC3832424
127. Nickels S, Truong T, Hein R, Stevens K, Buck K, Behrens S, Eilber U, Schmidt M, Haberle L, Vrieling A, Gaudet M, Figueroa J, Schoof N, Spurdle AB, Rudolph A, Fasching PA, Hopper JL, Makalic E, Schmidt DF, Southey MC, Beckmann MW, Ekici AB, Fletcher O, Gibson L, Silva Idos S, Peto J, Humphreys MK, Wang J, Cordina-Duverger E, Menegaux F, Nordestgaard BG, Bojesen SE, Lannig C, Anton-Culver H, Ziogas A, Bernstein L, Clarke CA, Brenner H, Muller H, Arndt V, Stegmaier C, Brauch H, Bruning T, Harth V, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Lambrechts D, Smeets D, Neven P,

- Paridaens R, Flesch-Janys D, Obi N, Wang-Gohrke S, Couch FJ, Olson JE, Vachon CM, Giles GG, Severi G, Baglietto L, Offit K, John EM, Miron A, Andrulis IL, Knight JA, Glendon G, Mulligan AM, Chanock SJ, Lissowska J, Liu J, Cox A, Cramp H, Connley D, Balasubramanian S, Dunning AM, Shah M, Trentham-Dietz A, Newcomb P, Titus L, Egan K, Cahoon EK, Rajaraman P, Sigurdson AJ, Doody MM, Guenel P, Pharoah PD, Schmidt MK, Hall P, Easton DF, Garcia-Closas M, Milne RL, Chang-Claude J. Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. *PLoS Genet* 9(3):e1003284, 2013. PMID: PMC3609648
128. Schwartz MP, Rogers RE, Singh SP, Lee JY, Loveland SG, Koepsel JT, Witze ES, Montanez-Sauri SI, Sung KE, Tokuda EY, Sharma Y, Everhart LM, Nguyen EH, Zaman MH, Beebe DJ, Ahn NG, Murphy WL, Anseth KS. A quantitative comparison of human HT-1080 fibrosarcoma cells and primary human dermal fibroblasts identifies a 3D migration mechanism with properties unique to the transformed phenotype. *PLoS One* 8(12):e81689, 2013. PMID: PMC3857815
129. Shanle EK, Zhao Z, Hawse J, Wisinski K, Keles S, Yuan M, Xu W. Research resource: global identification of estrogen receptor beta target genes in triple negative breast cancer cells. *Mol Endocrinol* 27(10):1762-75, 2013. PMID: PMC3787129
130. Sievers CK, Shanle EK, Bradfield CA, Xu W. Differential action of monohydroxylated polycyclic aromatic hydrocarbons with estrogen receptors alpha and beta. *Toxicol Sci* 132(2):359-67, 2013. PMID: PMC3595519
131. Smits BM, Haag JD, Rissman AI, Sharma D, Tran A, Schoenborn AA, Baird RC, Peiffer DS, Leinweber DQ, Muelbl MJ, Meilahn AL, Eichelberg MR, Leng N, Kendziorowski C, John MC, Powers PA, Alexander CM, Gould MN. The gene desert mammary carcinoma susceptibility locus *Mcs1a* regulates *Nr2f1* modifying mammary epithelial cell differentiation and proliferation. *PLoS Genet* 9(6):e1003549, 2013. PMID: PMC3681674
132. Strotman L, O'Connell R, Casavant BP, Berry SM, Sperger JM, Lang JM, Beebe DJ. Selective nucleic acid removal via exclusion (SNARE): capturing mRNA and DNA from a single sample. *Anal Chem* 85(20):9764-70, 2013. PMID: PMC3897163
133. Su X, Theberge AB, January CT, Beebe DJ. Effect of microculture on cell metabolism and biochemistry: do cells get stressed in microchannels? *Anal Chem* 85(3):1562-70, 2013. PMID: PMC3565071
134. Sung KE, Su X, Berthier E, Pehlke C, Friedl A, Beebe DJ. Understanding the impact of 2D and 3D fibroblast cultures on in vitro breast cancer models. *PLoS One* 8(10):e76373, 2013. PMID: PMC3790689
135. Thraen-Borowski KM, Trentham-Dietz A, Edwards DF, Koltyn KF, Colbert LH. Dose-response relationships between physical activity, social participation, and health-related quality of life in colorectal cancer survivors. *J Cancer Surviv* 7(3):369-78, 2013. PMID: PMC3737238
136. Wang J, Trentham-Dietz A, Hemming JD, Hedman CJ, Sprague BL. Serum factors and clinical characteristics associated with serum E-screen activity. *Cancer Epidemiol Biomarkers Prev* 22(5):962-71, 2013. PMID: PMC3726048
137. Warren Andersen S, Trentham-Dietz A, Gangnon RE, Hampton JM, Figueroa JD, Skinner HG, Engelman CD, Klein BE, Titus LJ, Newcomb PA. The associations between a polygenic score, reproductive and menstrual risk factors and breast cancer risk. *Breast Cancer Res Treat* 140(2):427-34, 2013. PMID: PMC3799826
138. Warrick JW, Young EW, Schmuck EG, Saupe KW, Beebe DJ. High-content adhesion assay to address limited cell samples. *Integr Biol (Camb)* 5(4):720-7, 2013. PMID: PMC3832292
139. Yarger JG, Babine RE, Bittner M, Shanle E, Xu W, Hershberger P, Nye SH. Structurally similar estradiol analogs uniquely alter the regulation of intracellular signaling pathways. *J Mol Endocrinol* 50(1):43-57, 2013. PMID: PMC3535725
140. Young EW, Berthier E, Beebe DJ. Assessment of enhanced autofluorescence and impact on cell microscopy for microfabricated thermoplastic devices. *Anal Chem* 85(1):44-9, 2013. PMID: PMC4017339
141. Berry SM, Chin EN, Jackson SS, Strotman LN, Goel M, Thompson NE, Alexander CM, Miyamoto S, Burgess RR, Beebe DJ. Weak protein-protein interactions revealed by immiscible filtration assisted by surface tension. *Anal Biochem* 447:133-40, 2014. PMID: PMC3897128

142. Berry SM, LaVanway AJ, Pezzi HM, Guckenberger DJ, Anderson MA, Loeb JM, Beebe DJ. HIV viral RNA extraction in wax immiscible filtration assisted by surface tension (IFAST) devices. *J Mol Diagn* 16(3):297-304, 2014.
143. Berry SM, Singh C, Lang JD, Strotman LN, Alarid ET, Beebe DJ. Streamlining gene expression analysis: integration of co-culture and mRNA purification. *Integr Biol (Camb)* 6(2):224-31, 2014. PMID: PMC3956049
144. Bischel LL, Casavant BP, Young PA, Eliceiri KW, Basu HS, Beebe DJ. A microfluidic coculture and multiphoton FAD analysis assay provides insight into the influence of the bone microenvironment on prostate cancer cells. *Integr Biol (Camb)* 6(6):627-35, 2014. PMID: PMC4077588
145. Bischel LL, Sung KE, Jimenez-Torres JA, Mader B, Keely PJ, Beebe DJ. The importance of being a lumen. *Faseb j* 28(11):4583-90, 2014. PMID: PMC4200326
146. Brinkman AM, Wu J, Ersland K, Xu W. Estrogen receptor alpha and aryl hydrocarbon receptor independent growth inhibitory effects of aminoflavone in breast cancer cells. *BMC Cancer* 14:344, 2014. PMID: PMC4037283
147. Carney CM, Muszynski JL, Strotman LN, Lewis SR, O'Connell RL, Beebe DJ, Theberge AB, Jorgensen JS. Cellular microenvironment dictates androgen production by murine fetal Leydig cells in primary culture. *Biol Reprod* 91(4):85, 2014.
148. Casavant BP, Guckenberger DJ, Beebe DJ, Berry SM. Efficient sample preparation from complex biological samples using a sliding lid for immobilized droplet extractions. *Anal Chem* 86(13):6355-62, 2014. PMID: PMC4079323
149. Casavant BP, Strotman LN, Tokar JJ, Thiede SM, Traynor AM, Ferguson JS, Lang JM, Beebe DJ. Paired diagnostic and pharmacodynamic analysis of rare non-small cell lung cancer cells enabled by the VerIFAST platform. *Lab Chip* 14(1):99-105, 2014. PMID: PMC3897162
150. Fan ZH, Beebe DJ. Lab on a chip and circulating tumor cells. *Lab Chip* 14(1):12-3, 2014.
151. Guckenberger DJ, Berthier E, Young EW, Beebe DJ. Fluorescence-based assessment of plasma-induced hydrophilicity in microfluidic devices via Nile Red adsorption and depletion. *Anal Chem* 86(15):7258-63, 2014. PMID: PMC4144722
152. Guckenberger DJ, Thomas PC, Rothbauer J, LaVanway AJ, Anderson M, Gilson D, Fawcett K, Berto T, Barrett K, Beebe DJ, Berry SM. A Combined Fabrication and Instrumentation Platform for Sample Preparation. *J Lab Autom* 19(3):267-74, 2014.
153. Lee KS, De Smet AA, Liu G, Staab MJ. High resolution ultrasound features of prostatic rib metastasis: a prospective feasibility study with implication in the high-risk prostate cancer patient. *Urol Oncol* 32(1):24.e7-11, 2014. PMID: PMC4160069
154. McLaughlin VH, Trentham-Dietz A, Hampton JM, Newcomb PA, Sprague BL. Lifestyle factors and the risk of a second breast cancer after ductal carcinoma in situ. *Cancer Epidemiol Biomarkers Prev* 23(3):450-60, 2014. PMID: PMC3951673
155. Montanez-Sauri SI, Beebe DJ, Sung KE. Microscale screening systems for 3D cellular microenvironments: platforms, advances, and challenges. *Cell Mol Life Sci* [Epub ahead of print], 2014.
156. Munoz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O, Berry DA, Burnside ES, Chang Y, Chisholm G, de Koning HJ, Ali Ergun M, Heijnsdijk EA, Huang H, Stout NK, Sprague BL, Trentham-Dietz A, Mandelblatt JS, Plevritis SK. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. *J Natl Cancer Inst* 106(11), 2014.
157. Munsell MF, Sprague BL, Berry DA, Chisholm G, Trentham-Dietz A. Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. *Epidemiol Rev* 36(1):114-36, 2014. PMID: PMC3873844
158. Sackmann EK, Berthier E, Schwantes EA, Fichtinger PS, Evans MD, Dziadzio LL, Huttenlocher A, Mathur SK, Beebe DJ. Characterizing asthma from a drop of blood using neutrophil chemotaxis. *Proc Natl Acad Sci U S A* 111(16):5813-8, 2014. PMID: PMC4000787
159. Sackmann EK, Fulton AL, Beebe DJ. The present and future role of microfluidics in biomedical research. *Nature* 507(7491):181-9, 2014.

160. Shelef MA, Sokolove J, Lahey LJ, Wagner CA, Sackmann EK, Warner TF, Wang Y, Beebe DJ, Robinson WH, Huttenlocher A. Peptidylarginine deiminase 4 contributes to tumor necrosis factor alpha-induced inflammatory arthritis. *Arthritis Rheumatol* 66(6):1482-91, 2014. PMID: PMC4148484
161. Simoncic U, Perlman S, Liu G, Staab MJ, Straus JE, Jeraj R. Comparison of NaF and FDG PET/CT for Assessment of Treatment Response in Castration-Resistant Prostate Cancers With Osseous Metastases. *Clin Genitourin Cancer* [Epub ahead of print], 2014.
162. Stout NK, Lee SJ, Schechter CB, Kerlikowske K, Alagoz O, Berry D, Buist DS, Cevik M, Chisholm G, de Koning HJ, Huang H, Hubbard RA, Miglioretti DL, Munsell MF, Trentham-Dietz A, van Ravesteyn NT, Tosteson AN, Mandelblatt JS. Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography. *J Natl Cancer Inst* 106(6):dju092, 2014. PMID: PMC4067109
163. Sung KE, Beebe DJ. Microfluidic 3D models of cancer. *Adv Drug Deliv Rev* 79-80c:68-78, 2014. PMID: PMC4258433
164. Warren Andersen S, Trentham-Dietz A, Gangnon RE, Hampton JM, Figueroa JD, Skinner HG, Engelman CD, Klein BE, Titus LJ, Egan KM, Newcomb PA. Reproductive windows, genetic loci, and breast cancer risk. *Ann Epidemiol* 24(5):376-82, 2014. PMID: PMC4164346
165. Warren Andersen S, Trentham-Dietz A, Gangnon RE, Hampton JM, Skinner HG, Engelman CD, Klein BE, Titus LJ, Egan KM, Newcomb PA. Breast cancer susceptibility loci in association with age at menarche, age at natural menopause and the reproductive lifespan. *Cancer Epidemiol* 38(1):62-5, 2014. PMID: PMC4023814
166. Adsit Robert, Wisinski K, Mattison R, Bailey H, Fiore M. A survey of baseline tobacco cessation clinical practices and receptivity to academic detailing. *Wisconsin Medical Journal* 113(3):143-6, 2016.

Presentations resulting from State Cancer Research Tax Check-Off:

1. University of Cincinnati, Department of Environmental Health, April 4-5, 2011 Cincinnati, Development of assays for screening environmental estrogens. [Xu]
2. Poster presentation in FASEB summer conference of Autoimmune Disease in 2010. [Xing]
3. DoD PCRP IMPACT meeting (Orlando, FL, March, 2011). [Beebe]
4. Microtechnology in Medicine and Biology Conference (Lucerne, Switzerland, April, 2011). [Beebe]
5. Correcting Breast DWI Distortion with Reversed Phase Encoding Direction. International Society for Magnetic Resonance in Medicine (May, 2012). [Kelcz]
6. Zhang Y, Hong H, Yang Y, Engle JW, Barnhart TE, Nickles RJ, Leigh B, **Cai W**. Positron Emission Tomography Imaging of CD105 Expression During Tumor Angiogenesis. Society of Nuclear Medicine 58th Annual Meeting, San Antonio, Texas, June 2011 (**# 296, Press Release, Oral Presentation**). [Cai]
7. Yang Y, Hong H, Zhang Y, **Cai W**. In Vivo Near-Infrared Fluorescence Imaging of CD105 Expression. Society of Nuclear Medicine 58th Annual Meeting, San Antonio, Texas, June 2011 (**# 232, Travel Award, Oral Presentation**). [Cai]
8. Zhang Y, Severin GW, Hong H, Engle JW, Yang Y, Barnhart TE, Leigh BR, Nickles RJ, **Cai W**. Positron Emission Tomography Imaging of CD105 Expression with ⁸⁹Zr-Df-TRC105. 2011 World Molecular Imaging Congress, San Diego, California, September 2011 (**# P194, Travel Award**). [Cai]
9. Yang Y, Zhang Y, Hong H, Leigh BR, **Cai W**. In Vivo Near-Infrared Fluorescence Imaging of CD105 Expression during Tumor Angiogenesis. 2011 World Molecular Imaging Congress, San Diego, California, September 2011 (**# P163**). [Cai]
10. Hong H, Shi J, Yang Y, Zhang Y, Wang X, **Cai W**. Fluorescent Zinc Oxide Nanowires Synthesized through Kinetics Control: a New Class of Agents for Targeted Optical Imaging. 2011 World Molecular Imaging Congress, San Diego, California, September 2011 (**# P130**). [Cai]
11. Hong H, Zhang Y, Severin GW, Yang Y, Engle JW, Barnhart TE, Leigh BR, Nickles RJ, **Cai W**. Dual-Modality Positron Emission Tomography and Near-Infrared Fluorescence Imaging of CD105 Expression in Breast Cancer Lung Metastasis. 2011 World Molecular Imaging Congress, San Diego, California, September 2011 (**# T210, Travel Award, Oral Presentation**). [Cai]
12. University of Cincinnati, Department of Environmental Health, April 4-5, 2011 Cincinnati, Development of assays for screening environmental estrogens. [Xu]